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ในการศึกษาน้ีได้ท าการพฒันาคาพาซิทีฟอิมมูโนเซนเซอร์แบบไม่ติดฉลากเพื่อการ
ตรวจวดัโปรตีนท่ีเป็นตวับ่งช้ีต่อโรค 2 ชนิดคือ YKL-39 และ YKL-40 ในระบบโฟลวอิ์นเจคชนั 
วิทยานิพนธ์ฉบบัน้ีได้แบ่งการศึกษาออกเป็น 2 ส่วน โดยส่วนแรกท าการศึกษาเก่ียวกบัการผลิต      
รีคอมบิแนนทโ์ปรตีน YKL-40 ในระบบการแสดงออกจากเซลล์แบคทีเรีย และเซลล์ของสัตวเ์ล้ียง
ลูกดว้ยนม เพื่อใช้ส าหรับการผลิตโพลีโคลนอลท่ีจ าเพาะต่อโปรตีน YKL-40 จากการศึกษาพบว่า 
YKL-40 แอนติบอดีมีความจ าเพาะและท าปฏิกิริยาอย่างสูงต่อโปรตีน YKL-40 เม่ือน า YKL-40    
โพลีโคนอลแอนติบอดีท่ีถูกท าให้บริสุทธ์ิ มาตรึงบนผิวอิเลคโทรดทองค าท างานโดยเทคนิคการ
เคลือบผวิแบบเรียงตวัชั้นเดียว พบวา่สภาวะท่ีเหมาะสมในการวิเคราะห์ของระบบอิมมูโนเซนเซอร์
ต่อโปรตีน YKL-40 จากแบคทีเรีย ไดแ้ก่ ปริมาณสารตวัอยา่ง 200 ไมโครลิตร อตัราการไหล 100 
ไมโครลิตรต่อนาที กรดไฮโดรคลอริคเขม้ขน้ 3.16 มิลลิโมลาร์ (พีเฮชเท่ากบั 2.5) เป็นสารรีเจเนอร์
เรต และบฟัเฟอร์ท่ีใช้คือ โซเดียมฟอสเฟตบฟัเฟอร์ความเขม้ขน้ 10 มิลลิโมลาร์ มีค่าพีเฮชท่ี 7.0 
ในขณะท่ี สภาวะท่ีเหมาะสมในการวิเคราะห์ของระบบอิมมูโนเซนเซอร์ต่อโปรตีน YKL-40 จาก
เซลล์ของสัตวเ์ล้ียงลูกด้วยนม ได้แก่ ปริมาณสารตวัอย่าง 250 ไมโครลิตร อตัราการไหล 100 
ไมโครลิตรต่อนาที กรดไฮโดรคลอริคเขม้ขน้ 3.16 มิลลิโมลาร์ (พีเฮชเท่ากบั 2.5) เป็นสารรีเจเนอร์
เรต และบฟัเฟอร์ท่ีใช้คือ โซเดียมฟอสเฟตบฟัเฟอร์ความเขม้ขน้ 10 มิลลิโมลาร์ มีค่าพีเฮชท่ี 7.0 
โดยภายใตส้ภาวะท่ีเหมาะสมต่อการวิเคราะห์ ทั้งสองระบบของอิมมูโนเซนเซอร์ต่อโปรตีน YKL-
40 พบช่วงความเป็นเส้นตรงระหวา่ง 0.1 ถึง 1,000 ไมโครกรัมต่อลิตร ในขณะท่ีค่าขีดจ ากดัท่ีต ่าสุด
ในการวดัอยูท่ี่ 0.07±0.01 ไมโครกรัมต่อลิตรในอิมมูโนเซนเซอร์ต่อโปรตีน YKL-40 จากแบคทีเรีย 
และ 0.08±0.02 ไมโครกรัมต่อลิตรในอิมมูโนเซนเซอร์ต่อโปรตีน YKL-40 จากเซลล์ของสัตวเ์ล้ียง
ลูกด้วยนม อิเลคโทรดท างานสามารถน ากลับมาใช้ใหม่ได้มากกว่า 40 รอบ ส าหรับอิมมูโน
เซนเซอร์ต่อโปรตีน YKL-40 จากแบคทีเรีย และ 50 รอบ ส าหรับอิมมูโนเซนเซอร์ต่อโปรตีน YKL-
40 จากเซลล์ของสัตว์เล้ียงลูกด้วยนม และระบบยงัแสดงความจ าเพาะต่อโปรตีน YKL-40 ใน
ตวัอยา่งแบบจ าลองพบวา่ การพฒันาระบบอิมมูโนเซนเซอร์ใหค้่าเปอร์เซ็นตก์ารคืนกลบัของวิธีการ
วิเคราะห์ในช่วงร้อยละ 98 ถึง 102 และในการตรวจวดัค่าโปรตีน YKL-40 ใน 4 ตวัอยา่งของคน
ปกติ 5 ตวัอย่างของมะเร็งเตา้นม และ 4 ตวัอย่างของมะเร็งสมอง ดว้ยวิธีอิมมูโนเซนเซอร์ต่อ
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โปรตีน YKL-40 จากเซลล์ของสัตวเ์ล้ียงลูกดว้ยนม ให้ค่าการตรวจวดัของโปรตีน YKL-40 ท่ีตรง
กบัวธีิมาตรฐาน ELISA อยา่งไรก็ตาม วิธีท่ีพฒันาข้ึนน้ีให้ค่าช่วงความเป็นเส้นตรงท่ีกวา้งกวา่ และ
มีค่าขีดจ ากดัท่ีต ่าสุดในการวดัต ่ากว่า อีกทั้งอิเลคโทรดท างานสามารถน ากลบัมาใช้ใหม่ไดห้ลาย
คร้ัง 
ส่วนท่ี 2 เป็นการศึกษาการพฒันาคาพาซิทีฟอิมมูโนเซนเซอร์เพื่อใชใ้นการตรวจวดัโปรตีน 
YKL-39 ซ่ึงเป็นโปรตีนท่ีใชใ้นการติดตามความกา้วหนา้ของโรคขอ้เส่ือม โพลีโคนอลแอนติบอดี
ต่อโปรตีน YKL-39 ถูกใชใ้นการตรึงกบัอิเลคโทรดทองท างานโดยเทคนิค การเคลือบผิวแบบเรียง
ตวัชั้นเดียวด้วยไทโอยูเรีย สภาวะท่ีเหมาะสมต่อการวิเคราะห์ของระบบของคาพาซิทีฟอิมมูโน
เซนเซอร์ต่อโปรตีน YKL-39 ได้แก่ ปริมาณสารตวัอย่าง 200 ไมโครลิตร อตัราการไหล 100 
ไมโครลิตรต่อนาที กรดไฮโดรคลอริคเขม้ขน้ 3.16 มิลลิโมลาร์ (พีเฮชเท่ากบั 2.5) เป็นสารรีเจเนอร์
เรต และบฟัเฟอร์ท่ีใช้คือ โซเดียมฟอสเฟตบฟัเฟอร์ความเขม้ขน้ 25 มิลลิโมลาร์ มีค่าพีเฮชท่ี 7.0 
ภายใตส้ภาวะท่ีเหมาะสมพบช่วงความเป็นเส้นตรงระหวา่ง 0.1 ไมโครกรัมต่อลิตร ถึง 1 มิลลิกรัม
ต่อลิตร ในขณะท่ีค่าขีดจ ากดัท่ีต ่าสุดในการวดัอยูท่ี่ 0.07±0.02 ไมโครกรัมต่อลิตร อิเล็กโทรดตรึง
โพลีโคนอลแอนติบอดีต่อโปรตีน YKL-39  สามารถน ากลบัมาใชใ้หม่ไดม้ากกวา่ 49 คร้ังโดยมีค่า
ส่วนเบ่ียงเบนมาตรฐานสัมพทัธ์ นอ้ยกว่าร้อยละ 5 ค่าท่ีไดใ้นการตรวจวดัค่าโปรตีน YKL-39 ใน
ตวัอยา่งเซลล ์ตวัอยา่งแบบจ าลอง และน ้ าไขขอ้ของผูป่้วยโรคขอ้เส่ือมพบวา่ วิธีคาพาซิทีฟอิมมูโน
เซนเซอร์ต่อโปรตีน YKL-39 และ วิธีมาตราฐาน ELISA พบวา่วิธีทั้งสองให้ค่าการตรวจวดัของ
โปรตีน YKL-39 ท่ีตรงกนั  
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THE DEVELOPMENT OF CAPACITIVE IMMUNOSENSORS TO DETECT 
CHITINASE-LIKE PROTEIN BIOMARKERS 
 
 In this study, a label-free capacitive immunosensor to detect two disease 
markers YKL-39 and YKL-40 has been established in a flow injection system. This 
thesis is divided into two parts. The first part involves expression of YKL-40 in 
bacterial and mammalian cell expression systems that were used as for production of 
anti-YKL-40 polyclonal antibody. The YKL-40 antibodies were highly specific and 
strongly reacting with YKL-40. The purified YKL-40 polyclonal antibody was 
immobilized on a gold working electrode via a self-assembled monolayer. Optimum 
operational conditions of the bacterial- YKL-40 immunosensor were a sample volume 
of 200 µL, a flow rate of 100 µL/min, HCl solution, pH 2.5, as regeneration solution 
and 10 mM sodium phosphate buffer, pH 7.0, as running buffer. For the mammalian- 
YKL-40 immunosensor, they were a sample volume of 250 µL, a flow rate of 100 
µL/min, HCl solution, pH 2.5, as a regeneration solution and 25 mM sodium 
phosphate buffer, pH 7.0, as running buffer. Under optimum operational conditions, 
both YKL-40 immunosensors gave a linear dynamic range between 0.1 and 1,000 
µg/L, with limit of detection of 0.07±0.01 µg/L for the bacterial-YKL-40 
immunosensor and 0.08±0.02 µg/L in the mammalian-YKL-40 immunosensor. The 
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reproducibility of working electrode can be regenerated up to 40 cycles for the 
bacterial-YKL-40 immunosensor and 50 cycles for the mammalian-YKL-40 
immunosensor. The system also showed good selectivity towards YKL-40. In model 
samples, the newly-developed capacitive immunosensor provided good recovery in a 
range of 98 to 102%. The serum level of YKL-40 in 4 healthy people, 5 breast cancer 
patients and 4 glioblastoma patients was detected with the mammalian-YKL-40 
immunosensor and the results agreed with the standard ELISA method. However, this 
developed method offered greater advantages with a broader linear range, lower limit 
of detection and multiple uses of the antibody-immobilized electrode. 
 In the second part, a capacitive immunosensor for detection YKL-39 as 
osteoarthritis biomarker was developed.  Antibody against YKL-39 was immobilized 
on a gold working electrode via a self-assembled thiourea monolayer. Optimum 
operational conditions were a sample volume of 200 µL, a flow rate of 100 µL/min, 
HCl solution, pH 2.5, as a regeneration solution and 25 mM sodium phosphate buffer, 
pH 7.0, as running buffer. The linear detection range was between 0.1 µg/L and 1 
mg/L with the detection limit of 0.07±0.02 µg/L. The immobilized anti-YKL-39 
antibody on gold electrode was stable and after regeneration good reproducibility of 
the signal could be obtained up to 49 times with an RSD lower than 5%. Good 
agreement was obtained when YKL-39 concentrations of cell lysate, model samples 
and synovial fluid were determined by the YKL-39 capacitive immunosensor system 
as compared to the ELISA method.  
 
School of Biochemistry                        Student’s signature                                    
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CHAPTER I 
INTRODUCTION 
 
1.1  YKL-40 as a cancer marker  
YKL-40 was originally identified a glycoprotein secreted in vitro in large 
amounts by the human osteosarcoma cell line MG-63 (Johansen, Williamson and Rice 
et al., 1992). The named protein “YKL-40” based on its three NH2-terminal amino 
acids tyrosine (Y), lysine (K), and leucine (L) and its molecular weight of 40 kDa 
(Johansen et al., 1992). It is also known as Chitinase-3-like protein 1 (CHI3L1) 
(Rehli, Krause and Andreesen, 1997), or human cartilage glycoprotein-39 (HC gp-39) 
(Hakala, White and Recklies, 1993). The complete amino acid sequence of the human 
YKL-40 was published in 1993. It belongs to family 18 glycosyl hydrolases (Hakala 
et al., 1993). 
The crystallographic three-dimensional structure of human YKL-40 displays 
the typical fold found in all family 18 glycosyl hydrolases (Fusetti, Pijning, Kalk et 
al., 2003). The structure is divided into two globular domains: a big core domain   
consists of a (β/α)8 domain structure with a triose-phosphate isomerase (TIM) barrel 
fold, and a small α/β domain, composed of five antiparallel β-strands and one a-helix 
that is inserted in the loop between strand β7 and helix α7 of the TIM barrel. The TIM 
barrel domain of YKL-40 contains a GlcNAc binding groove responsible for binding 
with chitin fragments (Fuseeti et al., 2003). YKL-40 catalytically inactive since two 
 
 
 
 
 
 
 
 
2 
 
amino acid residues (Asp140-Glu) that are normally found in the catalytic motif 
D138xD140xE of true chitinases are mutated to alanine and leucine, respectively  
(Figure 1.1) (Houston, Recklies, Krupa et al., 2003). YKL-40 also contains a heparin 
binding motif (GRRDKQH, residues 143-149) (Shackelton, Mann, and Millis, 1995) 
located on a surface loop (Fusetti et al., 2003). YKL-40 contains five cysteine, four of 
which are involved in two disulfide bonds (C
26
-C
51
 and C
300
-C
364
) (Fusetti et al., 
2003). 
 
 
Figure 1.1  The crystal structure of YKL-40. Red color in the ribbon representation 
indicates α-helices and blue indicates β-strands. The side chain of Leu140 is shown as 
black stick. The two disulfide bonds are shown in green. Solvent-exposed aromatic 
residues lining the binding cleft are shown as sticks with magenta carbons and pink 
circle representation indicates the heparin binding motif (Houston et al., 2003).  
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A number of studies demonstrate elevated YKL-40 expression in cancer 
tissues from breast (Johansen, Christensen, Riisbro et al., 2003), colorectal (Cintin, 
Johansen, Christensen et al., 1999), small cell lung (Johansen, Drivsholm, Price et al., 
2004), ovary (Dupont, Tanwar, Thaler et al., 2004), glioblastoma (Tanwar, Gilbert, 
and Holland et al., 2002), and prostate (Brasso, Christensen, Johansen et al., 2006). 
However, exact physiological functions of YKL-40 protein are still unclear. A recent 
review article suggested that YKL-40 may play a role in the proliferation and 
differentiation of malignant cells, by protecting cancer cells from undergoing 
apoptosis, as well as stimulating angiogenesis. YKL-40 may have effects on 
extracellular tissue remodeling, and stimulate fibroblasts surrounding the tumor tissue 
(Johansen, 2006). In addition, YKL-40 may as well play a role in inflammation of 
non-malignant tissues.  
In 2009, Shao and co-worker reported that YKL-40 involves in the regulatory 
pathways that mediate vascular effects (Shao, Hamel, Petersen et al., 2009). Through 
tumor angiogenesis, YKL-40 binds to the heparin sulfates of Syndecan-1, a major 
proteoglycan on the epithelial cell surface, and activates (phosphorylates) focal 
adhesion kinase (FAK) together with integrin αvβ3. This induces angiogenesis 
through the subsequent activation of MAP/Erk kinase (Shao et al., 2009). FAK can 
also activate phosphatidylinositol 3 kinase (PI3K)/Akt signaling pathways that are 
critical for cell survival, differentiation, and fibrogenesis (Horowitz, Rogers, Sharma 
et al., 2007) (Figure 1.2). 
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Figure 1.2  The proposed signaling pathways of YKL-40 in cellular proliferation, 
adhesion, and survival. BRP-39 binds to the heparan sulfate of Syndecan-1, a major 
cell surface proteoglycan. Along with integrin αvβ3, the binding activates focal 
adhesion kinase (FAK). Phosphorylated FAK (p-FAK) activates downstream 
signaling molecules, including MAP or Erk (p-Erk) kinase, phosphatidylinositol 3 
kinase (p-PI3K), and Akt (p-Akt) (Lee, Da Silva, Dela Cruz et al., 2011).  
  
The plasma levels of YKL-40 were normally determined by commercial 
enzyme-linked immunoassays (ELISA).   In a report by Harvey and co-worker (1998) 
using the ELISA kit provided by Quidel, Santa Clara, CA, USA, (the plasma levels of 
YKL-40 from both male and female were highly correlated with ages (p < 0.001) and 
the median plasma YKL-40 level in healthy subjects (n = 245) was 40 μg/L (Harvey, 
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Weisman, O’Dell et al., 1998; Johansen, Jensen, Roslind et al., 2006; Johansen, 
Lottenburger, and Nielsen, 2008; Johansen, Bojesen, Mylin et al., 2009). 
In another report, Johansen and co-worker reported that patients with breast 
cancer had significantly increased serum YKL-40. They measured the level of YKL-
40 from breast cancer patients and found that the median serum YKL-40 in patients 
with visceral and bone metastases were 328 and 157.1 µg/L, respectively. Such values 
were significantly higher than the value of healthy subjects (99 µg/L, p < 0.001). The 
survival rates after 18 months were 24% for patients with high level of serum YKL-40 
(>207 µg/L) and 60% for patients with normal level of serum YKL-40. The highest 
level of YKL-40 were found in patients with short survival, while normal levels of 
YKL-40 were found in longer survival patients as shown in Figure 1.3 (Johansen, 
Cintin, Jørgensen et al., 1995). The results suggested that serum YKL-40 might be 
used as a prognostic marker in breast cancer patients. In another study, associations 
were observed with the preoperative serum YKL-40 out of 271 patients with primary 
breast cancer in relation to relapse-free survival and overall survival. The median 
follow-up time was 5.9 years. The median serum YKL-40 concentration in the 
patients was 57 μg/L (range, 22 to 688 μg/L) compared to the serum YKL-40 in 
healthy females. Of which, 19% of the patients had high serum YKL-40. Patients with 
high serum YKL-40 had shorter relapse-free interval and survival than patients with 
normal serum YKL-40 (Johansen et al., 2003). 
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Figure 1.3  Individual serum YKL-40 concentrations in breast cancer patients in 
relation to survival time. The serum YKL-40 was determined by radioimmunoassay 
(Johansen et al., 2006).  
 
Serum YKL-40 was also determined in 603 patients with colorectal cancer 
(Cintin et al., 1999).  The median serum YKL-40 concentration in the cancer patients 
was 180 µg/L (range, 56 to 2709 µg/L). Survival after operation was registered, and 
the median of the follow-up time was 61 months. Three hundred and forty patients 
died, for which 16% of the patients with Dukes’ A (tumor confined within the bowel 
wall, no lymph-node metastases), 26% with Dukes’ B (tumor extending through the 
bowel wall, no lymph-node metastases), 19% with Dukes’ C (regional lymph-node 
metastases) and 39% with Dukes’ D (disseminated disease) had high serum YKL-40 
levels. Analysis of serum YKL-40 as a continuous variable showed an association 
between increased serum YKL-40 and short survival (p < 0.0001). Patients with high 
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preoperative serum YKL-40 concentration had significantly shorter survival than 
patients with normal YKL-40 (Cintin et al., 1999). Serum YKL-40 decreased 
significantly after curative operation for colorectal cancer in patients with high 
preoperative serum YKL-40 (Cintin, Johansen, Christensen et al., 2002), indicating 
that serum YKL-40 may reflect tumor burden. 
In ovarian cancer, the serum YKL-40 levels were determined by ELISA for 46 
healthy subjects, 61 high-risk individuals, 33 patients with benign gynecologic 
processes, and 50 preoperative patients subsequently diagnosed with predominantly 
early-stage ovarian cancer. The results showed that the median YKL-40 level was 28 
µg/L (range, 15 to 166 µg/L) for healthy subjects, 36 µg/L (range, 9 to 69 µg/L) for 
high-risk individuals without prior cancer, 44.5 µg/L (range, 5 to 133 µg/L) for high-
risk patients with prior breast cancer, and 38 µg/L (range, 5 to 67 µg/L) for 
individuals with benign gynecologic processes. The median of preoperative YKL-40 
level for ovarian cancer patients was 94 µg/L (range, 17 to 517 µg/L). Twenty of 31 
early-stage patients (state I and II) had elevated serum YKL-40 level (Dupont et al., 
2004). The median level of plasma YKL-40 in the stage III patient was 168 µg/L 
(range, 32 to 1808 µg/L) and significantly higher compared to the plasma level in 
healthy women (median 35 µg/L, range 20 to 130 µg/L). In addition, preoperative 
serum YKL-40 was elevated in 74% to 91% of patients with ovarian cancer stage III 
(tumor growth involving one or both ovaries with wide-spread intraperitoneal 
metastases) and stage IV (disseminated disease) and 55% of ovarian cancer patient 
had high plasma YKL-40 at the time of relapse and had significantly shorter survival 
than patients with normal level (Høgdall, Johansen, Kjaer et al., 2003; Dehn, Høgdall, 
Johansen et al., 2003).    
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For small cell lung cancer, the serum YKL-40 level in 131 patients was 
determined by RIA, giving the median level serum of YKL-40 in the patients to be 
172 μg/L (range, 48 to 2481 μg/L) and significantly elevated (p < 0.001) compared 
with the level in the healthy age-matched controls (median 102 μg/L, range 38 to 514 
μg/L). The results also showed that 22% of the patients with low grade cancer and 
40% of the patients with high grade cancer had elevated serum YKL-40. The median 
survival time was only 5.1 months for patients with elevated serum YKL-40 and 9 
months for patients with normal serum YKL-40. Also, patients with elevated serum 
YKL-40 had increased hazard for death within the first 6 months after the start of 
chemotherapy compared to patients with normal serum YKL-40 (Johansen et al., 
2004).  
In case of prostate carcinoma, the serum level of YKL-40 in 93 healthy Danish 
men older than 25 years (median age of 51 years, range 26 to 73 years) was 
determined by ELISA assay. The median serum YKL-40 in the control group was 47 
µg/L (range 20 to 184 µg/L), whereas the median serum concentration of YKL-40 in 
the patients with prostate carcinoma was 112 µg/L (range 20 to 2080 µg/L) was 
significantly higher compared to the levels in healthy men and 43% of patients with 
metastatic prostate cancer (p < 0.001) (Brasso et al., 2006). 
For glioblastoma, YKL-40 mRNA was detected in the glioblastoma samples 
with a range of 3- to 62-fold higher than mRNA level in normal brain samples. The 
serum level of YKL-40 in glioblastoma patients in 45 patients was   130 µg/L, and 
ranges from 38 to 654 µg/L. The analysis on serum YKL-40 in glioblastoma patients 
was found to be correlated with the presence of tumor and tumor grade or burden. 
Seventy tow percentage of patients with glioblastoma multiform and 57% with lower 
 
 
 
 
 
 
 
 
9 
 
grade gliomas had high serum YKL-40 (Tanwar et al., 2002). The data of some of the 
clinical studies on the serum YKL-40 level of cancer patients and the percentage of 
patients with elevated high serum YKL-40 is summarized in Table 1.1.  
 
Table 1.1  Serum levels of YKL-40 (μg/L) in cancer patients and the percentage of 
patients with elevated serum YKL-40. 
* The percentage (%) of patients with elevated serum YKL-40 compared to the age-
adjusted serum YKL-40 level in healthy subjects.  
 
Based on the literature review, YKL-40 has been received attention as a 
potential prognostic marker for cancer development and health prospects of cancer 
patients. Diagnostic application of this protein needs sensitive analytical approach for 
the detection of YKL-40 in cancer serum samples. In this study, we describe 
establishment of YKL-40 detection using electrochemical-based immunosensor.  
 
 
Diagnosis n 
YKL-40 
(µg/L) 
High YKL-40 
(%)* 
Reference 
Breast cancer 271 57 (22-688) 19 (Johansen  et al., 2003) 
Colorectal cancer 603 180 (56-2709) 26 (Cintin et al., 1999) 
Ovarian cancer 50 94 (17-517) 72 (Dupont et al., 2004) 
Small cell lung cancer 131 172 (48-2481) 32 (Johansen et al., 2004) 
prostate cancer 153 112 (20-2080) 43 (Brasso et al., 2006) 
Glioblastoma 45 130 (38-654) 72 (Tanwar et al., 2002) 
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1.1.1  Methods for the determination of YKL-40 in tissues and body fluids 
 Several methods have been proposed for quantitative analysis of YKL-40 in 
blood serum samples and some details are provided as listed below: 
 
Immunohistochemical analysis 
Immunohistochemical procedures for the detection of YKL-40 protein 
expression in biopsies of human tissues have been described using routine staining 
methods for frozen or formalin-fixed paraffin-embedded tissues. An affinity purified 
rabbit antibody against human YKL-40 (Johansen, Møller, Price et al., 1997; 
Johansen, Baslund, Garbarsch et al., 1999; Johansen, Christoffersen, Møller et al., 
2000; Volck, Price, Johansen et al., 1998; Volck, Østergaard, Johansen et al., 1999; 
Volck, Johansen, Stoltenberg et al., 2001; Kawasaki, Hasegawa, Kondo et al., 2001) 
or a mouse monoclonal antibody against human YKL-40 (Baeten, Boots, 
Steenbakkers et al., 2000) were used as primary antibodies. The methodology was 
proven functional for different human tissues: such as liver (Johansen et al., 1997; 
2000), bone marrow (Volck et al., 1998), inflamed arteries (Johansen et al., 1999), 
cartilage (Volck et al., 1999, 2001), synovial membrane (Baeten et al., 2000; Volck et 
al., 2001), peripheral blood mononuclear cells (Baeten et al., 2000) and 
atherosclerotic vessels (Nishikawa and Millis, 2003). 
 
Detection of serum YKL-40 by different enzyme-linked immuno assays 
The first human YKL-40 assay was a radioimmunoassay (RIA) using a rabbit 
polyclonal antibody against human YKL-40 (Johansen, Jensen, and Price et al., 
1993). The assay runs over two days, involves 20 hr of incubation at room 
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temperature and requires sample dilution. The sensitivity of the RIA is 10 µg/L and 
the percentage of recovery 100.3% (Johansen et al., 1993). 
A sandwich-type enzyme-linked immunosorbent assay (ELISA) for 
measurements of human YKL-40 was later developed and is now commercially 
available from Quidel, Santa Clara, CA, USA. This assay uses a 96-well plate coated 
with streptavidin and a biotinylated murine monoclonal antibody against human 
YKL-40, an alkaline phosphatase (AP)-conjugated rabbit polyclonal antibody to 
YKL-40, and a chromogenic substrate. In the first step, standards, and test specimens 
are added to the avidin coated wells along with the captured solution containing a 
biotinylated F(ab) fragment of a murine monoclonal antibody to YKL-40. The 
monoclonal antibody binds to YKL-40   standards, or specimens, while the biotin 
binds to the avidin on the microwell plate, leading to immobilization of the antibody. 
After an incubation period, a wash cycle removes any unbound materials. In the 
second step, alkaline phosphatase conjugated rabbit anti-YKL-40 is added to each 
well. The enzyme conjugated anti-YKL-40 binds to the immobilized YKL-40 
captured in the first step. After an incubation period, a wash cycle removes any 
unbound conjugates. In the third step, p-nitrophenyl phosphate, a chromogenic 
substrate solution, is added to the wells. The bound alkaline phosphatase reacts with 
the substrate, forming yellow color. After an incubation period, the reaction is stopped 
chemically, and the color intensity is measured spectrophotometically at A450. The 
color intensity of the reaction mixture is proportional to the concentration of YKL-40 
present in the test specimens, standards and controls. Results are calculated from the 
generated standard curve using linear regression analysis. The ELISA is finished 
within 4 hr, is carried out at room temperature and does not require sample dilution 
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(only if the concentration of YKL-40 in the sample is very high). The lower limit of 
quantification is 20 µg/L and the linear range is 20 to 300 µg/L. The sensitivity of the 
ELISA from previous study is 8 µg/L and the percentage of recovery 102% (Harvey 
et al., 1998).  
Another commercial ELISA kit for determining YKL-40 serum is available 
from Shanghai BlueGene Biotech CO., LTD (Ma, Wang, Du et al., 2012). The YKL-
40 enzyme linked immunosorbent assay is called a competitive ELISA. The microtiter 
plate provided in this kit is pre-coated with anti-YKL-40. Standards or samples are 
added to the microtiter plate wells. Then, YKL-40 conjugated with HRP (YKL-40-
HRP) was added, mixed   and incubated 1 hr.  After incubation, the wells are 
thoroughly washed to remove all unbound components. The wells are then incubated 
with a chromogenic substrate for horse radish peroxidase (HRP) enzyme. The product 
of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop 
solution is added to 1 N HCl to the reaction, which will then turn   yellow. The 
intensity of color is measured spectrophotometically at 450 nm in a microplate reader. 
The intensity of the color is inversely proportional to the YKL-40 concentration since 
YKL-40 from samples and YKL-40-HRP conjugated compete for the anti-YKL-40 
antibody binding site. Since the number of sites is limited, as more sites are occupied 
by YKL-40 from the sample, ewer sites are left to bind the YKL40-HRP conjugate. 
This method recommends the lower limit of quantification to be 2.5 µg/L and linear 
range 2.5 to 250 µg/L.  
Non-commercial ELISA was also developed and used for a small-scale 
detection of YKL-40 in clinical trials. The YKL-40 ELISA was carried out by coating 
a 96-well plate with a mouse monoclonal antibody against human YKL-40 and a HRP 
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conjugated mouse monoclonal antibody against human YKL-40 was used as a 
detection antibody. The linear range of this approach was reported to be 0-300 µg/L 
(Vos, Steenbakkers, Miltenburg et al., 2000).  
Later, an indirect competition ELISA was developed for detecting serum 
YKL-40 in guinea pigs using   polyclonal anti-guinea pig YKL-40 antibody produced 
in hens and extracted from the egg yolk. This assay can also determine rabbit YKL-
40, but not rat or mice YKL-40. The lower limit of detected was reported to be 10 
µg/L and a linear range was 10 to 320 µg/L (De Ceuninck, Pastoureau, Agnellet et al., 
2001). 
Since the existing method for detection of low level of YKL-40 is still not 
optimal, analytical properties to improve   sensitivity, detection limit, time of analysis, 
and cost are required. A lower detection limit and sensitivity would, for instance, be 
in support of a better detection of the gradually appearing increase in the body level of 
YKL-40. Over the past two decades, the quality of biosensor has improved a 
dramatically and this analytical tool is currently accepted and qualified for improving 
bio-analyte detection in clinical samples. The principles of biosensor will be 
introduced and its functional features will be described. 
 
1.2  YKL-39 as an ostioartitris marker 
 YKL-39 (also known as chitinase3-like2, CHI3L2) is a non-glycosylated 
YKL-40 homolog. It was originally isolated as one of the major proteins secreted in 
primary culture of human articular chondrocytes and accounts for 4% of the total 
proteins secreted in chondrocyte-conditioned medium (Hu, Trinh, Figueira et al., 
1996). YKL-39 is more closely related in size and sequence to YKL-40 than other 
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members of the GH-18 family with more than 50% identity. Similar to YKL-40, the 
name of YKL-39 was given based on its three N-terminal amino acids: tyrosine (Y), 
lysine (K) and leucine (L) and its apparent molecular weight of 39 kDa. YKL-39 was 
co-purified with YKL-40 (Hu et al., 1996). When the secreted protein YKL-40 from 
human articular chondrocyte culture was harvested and then fractionated by Sephacryl 
S-300 HR chromatography, the N-terminal  sequencing data displayed the presence of  
two amino acid sequences, one of which had the sequence of YKLVXYYTSWSQYR 
(YKL-40), whereas the other had the sequence of YKLVXYFTNWSQDR (later being 
identified as YKL-39) (Hu et al., 1996). Functional characterization showed that 
YKL-40 was different from YKL-39, in that YKL-40 contains the heparin binding 
sequence at the C-terminus. Therefore, YKL-40 can bind to heparin with high 
affinity, whereas YKL-39 does not contain heparin binding sequence. SDS-PAGE 
analysis showed that YKL-39 had a molecular mass slightly smaller than YKL-40 
(Figure 1.4, Land 1a and 2a). Staining of the SDS-PAGE gel for carbohydrate showed 
that YKL-39 is not a glycoprotein (Figure 1.4, Lane 2b), but YKL-40 is a 
glycoprotein (Figure 1.4, Lane 1b).    
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Figure 1.4  SDS-PAGE analysis of YKL-39 and YKL-40; (left-hand panel) 
Coomassie Brilliant Blue stain; (right-hand panel). Glycoprotein stains using the 
Sigma glycoprotein detection. Lane MW, molecular mass standards; Lane 1a and 1b, 
YKL-40; Lane 2a and 2b, YKL-39 (Hu et al., 1996). 
 
A complete YKL-39 cDNA encodes a single polypeptide chain of 385 amino 
acids, which contains the 21-amino acid signal peptide. The mature protein, after 
removal of the signal peptide, has a length of 364 amino acids and a calculated 
molecular mass of 40,825 Da. Within the conserved sequence motif region, the 
glutamic acid, which is essential for catalytic activity of human chitinases, is 
substituted with isoleucine, thus making YKL-39 lack chitinase activity (Hu et al., 
1996).  
In addition to be predominantly expressed in chondrocytes and synoviocytes 
(Hu et al., 1996), YKL-39 mRNA was also detected in lung and heart and 
glioblastoma cells,  but not in brain, spleen, pancreas, and liver (Kavsan, Dmitrenko,  
Boyko et al., 2008 and Hu et al., 1996). 
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YKL-39 is currently recognized as a biochemical marker for the activation of 
chondrocytes and the progress of the osteoarthritis in human (Knorr, Obermayr, 
Bartnik et al., 2003). Real time PCR and DNA microarray analysis suggested that 
YKL-39 mRNA is significantly up-regulated in cartilage of patients with 
osteoarthritis and the YKL-39 mRNA expression was correlated with collagen type 2 
up-regulations, while YKL-40 mRNA showed no significant up-regulation in 
osteoarthritis cartilage (Steck, Breit, Breusch et al., 2002). Another study showed that 
the mRNA expression of YKL-39 was up-regulated both in early degenerative and 
late stage osteoarthritis, while YKL-40 was significantly down-regulated during the 
progression of osteoarthritis (Knorr et al., 2003). Proteomic analysis identified YKL-
39, but not YKL-40, to be secreted by human osteoarthritic cartilage in culture (De 
Ceuninck, Marcheteau, Berger et al., 2005).  YKL-39 has been proposed to contribute 
to the disease progression and may be an induction of autoimmune response of 
osteoarthritis (Sekine, Masuko-Hongo, Matsui et al., 2001; Du et al., 2005). ELISA 
and western blotting analysis showed that YKL-39 antibodies were detected 8% in 
human serum in patients with rheumatoid arthritis (RA), while only 1% of patients 
with RA had autoantibodies. The detection of autoantibody during initial cartilage 
degeneration in osteoarthritis in early stage knee osteoarthritis suggested a specific 
immune response to YKL-39 (Du et al., 2005) and that YKL-39 may be used as a 
candidate biomarker to monitor the progression of ostioartitris. Other lines of 
evidence have supported the important roles of YKL-39 in osteoarthritis. For 
example, immunization with recombinant YKL-39 induced arthritis in different 
strains of mice tested, which BALB/c mice was most susceptible (Sakata, Masuko-
Hongo, Tsuruha et al., 2002). Histological examination revealed synovial 
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proliferation and irregularity of the cartilage surface in BALB/c mice (Figure 1.5). 
After injection of purified YKL-39, not only anti-YKL-39 antibody was detected, but 
also the antibody against type II collagen, suggesting the spreading of autoimmune 
reactions (Sakata et al., 2002). This animal model suggested that YKL-39 acted as an 
inducer of autoimmune processes related to arthritis. Another biological activity of 
YKL-39 is it may play a role in tissue remodeling (Sakata et al., 2002). Participation 
of YKL-39 in tissue remodeling was suggested on the basis of its high level in 
chondrocyte cultures and close homology to YKL-40 that was shown to induce cell 
proliferation and migration. Moreover, recently report showed that YKL-39 also 
activated cell signaling regulated by ERK1/ERK2 kinases in human embryonic 
kidney (HEK293) and human glioblastoma (U87) cells (Areshkov and Kavsan, 2010). 
As well as YKL-39 also found in the synovial fluid of an ostioartitris patient, Jurkat 
cell lysate, and U937 cell lysate (Ranok, Khunkaewla and Suginta, 2013).  
 
 
Figure 1.5  YKL-39 induced arthritis in BALB/c mice. The right foot pad of a 
control mouse (left-hand panel) and  the right foot pad of an YKL-39 (50 g) 
immunized BALB/c mouse 30 days after the first immunization (right-hand panel) 
(Sakata et al., 2002). 
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 Osteoarthritis is the most common type of arthritis and is seen especially 
among older people. Sometimes it is called degenerative joint disease. Osteoarthritis 
can affect any joint, but it occurs most often in knees, hips, lower back and neck, 
small joints of the fingers and the bases of the thumb and big toe. Osteoarthritis 
mostly affects cartilage, the hard but smooth tissue that covers the ends of bones 
where they meet to form a joint.  The diagnosis of osteoarthritis is currently based on 
radiographic criteria (e.g. joint space width) and clinical symptoms (e.g. pain and loss 
of function). However, the limitations of radiography (e.g. technical issues, precision 
and sensitivity) have led to research into alternative parameters to detect osteoarthritic 
changes in the joints in an early stage of the disease in a quantitative, reliable, and 
sensitive manner. The measurement of biochemical markers in blood, urine or 
synovial fluid samples could reflect dynamic and quantitative changes in joint 
remodeling and therefore disease progression (Mobasheri and Henrotin, 2010; 
Lamers, van Nesselrooij, Kraus et al., 2005). The C-terminal telopeptide of collagen 
type II (CTX-II, Kim, Park, Min et al., 2013), cartilage oligomeric matrix proteins 
(COMPs, Hong, Park, Jang et al., 2012), various matrix metalloproteinases (Bay-
Jensen, Liu, Byrjalsen et al., 2011; Gargiulo, Gamba, Poli et al., 2014) and finally 
YKL-39 (Knorr et al., 2003; Steck et al., 2002; Ranok et al., 2013) were identified as 
potentially measurable biomarkers for osteoarthritis. The standard analytical method 
for the detection biomarkers in body fluids is the ELISA techinique, which requires an 
antibody against the chosen indicator molecule and an enzyme-labeled secondary 
antibody to generate the final signal. However, ELISA methods are time consuming 
and involve relatively expensive equipment. To improve the alternative method for 
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detection in early stage in ostioartitris patient we chose the YKL-39, the biomarker for 
early stage of ostioartitris patient (Knorr et al., 2003), by capacitive immunosensor.   
 
1.3  The principle of capacitive electrochemical immunosensing 
 Capacitive immunosensors are a special form of biosensors, which are 
analytical tools using specific biological recognition elements (BRE) (e.g. enzymes, 
tissue, microorganisms, antibodies, cell receptors etc.) in intimate contact on a 
suitable physicochemical transducer device that converts the interaction of the BRE 
with substrate into a quantifiable electric signal. Biosensors usually generate an 
electronic signal which is proportional to the concentration of a specific analyte or a 
group of analytes (Sharma, Shegal, and Kumar, 2003). The general working principle 
of biosensors is shown in Figure 1.6 in a schematic drawing. 
 
 
Figure 1.6  The principle of a biosensor. 
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 Biosensors can be divided into two categories, namely the catalytic and the 
affinity-based biosensors. Bio-catalytic biosensors use isolated enzymes or whole 
cells with their totality of enzymes as BREs that catalyze a signaling biochemical 
reaction with the substrate of the immobilized enzyme, which usually then is the 
analyte. In enzyme-based biosensors, for example, substrate molecules are 
continuously converted into the corresponding product molecules; regeneration of the 
BRE needs interaction with a co-factor, which accordingly changes chemical (redox) 
state and the upcoming converted co-factor is a side product of the enzymatic action 
on substrate (Yang, 2012). Monitored with a suitable transducer of enzyme-biosensors 
as analytically useful signal is then the consumption of substrate, the generation of 
product of enzyme activity, or the co-factor in initial or final version state (Byfield 
and Abuknesha, 1994; Dong and Chen, 2002). Common analytes for enzyme 
biosensors are small organic molecules, and most popular case is the glucose oxidase-
based glucose biosensor that is used by the millions of people around the world with 
diabetes for measuring on hourly basis their blood sugar levels. 
 Bio-affinity-based biosensors, designed to monitor substrate/BRE conjugation 
and not chemical turnover, use binding proteins such as lactins, receptors, nucleic 
acids, membranes, whole cells, antibodies, or antibody-related substances, for specific 
bimolecular recognition (Rogger, 2000). According to the type of the BREs, affinity 
biosensor can be classified as DNA biosensors, receptor biosensors and 
immunosensors. 
 Immunosensors are compact analytical devices in which the event of 
formation of antigen antibody complexes is detected and converted, by means of a 
transducer, to an electrical signal, which can be processed, recorded and displayed. 
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Immunosensors are divided into two main categories; label-free (direct method) and 
labeled (indirect method). The labeled immunosensor are derived from the 
immunoassay technology, where signal generation is significantly facilitated. This 
type of sensor requires the target analyte or secondary antibody to be labeled, and can 
undoubtedly be potent; however, there are significant issues associated with the 
process of labeling, attaining reproducible changes at the surface and in the inherently 
multistep nature of analyses. Label-free immunosensors rely on the detection of 
physical change during the immune complex formation. Such changes have been 
measured using optical, piezoelectric and electrochemical transducers. Label-free 
approaches benefit considerably from being single step, fast, and cheap and they make 
real time measurement possible. 
 In electrochemical immunosensors, the event of the formation of antigen-
antibody complex is converted into an electrical signal: amperometry, voltammetry or 
electrochemical impedance spectroscopy (EIS) are schemes that can help to translate 
the binding event into a readable measure (Centi et al., 2009). The most common type 
of amperometric/voltammetric immunosensors can be regarded as ELISA tests with 
electrochemical detection, where redox species generated by a redox enzyme 
(enzymatic label) are converted into a measurable current. Whereas, EIS is a label-
free method that measures electrode capacitance changes produced by restructuring of 
the interfacial Helmholtz double-layer on antigen binding. EIS immunosensing is an 
effective and sensitive method to probe the interfacial properties of modified 
electrode and to monitoring the binding of the antigen-antibody but EIS requires 
specific hardware and software and the acquired data is complex. A simpler method to 
detecting the binding of the antigen-antibody due to capacitance changes is the 
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analysis of the current response on application of a potential pulse (Berggren, 
Bjarnason, and Johansson, 2001; Berggren and Johannsson, 1997 and Limbut, 
Kanatharana, Mattiasson et al., 2006a,b). 
 Capacitive immunosensors have been report by Newman and co-worker as 
early as 1986. They reported that antibody-antigen reaction, which occur at the device 
surface, produce significant and reversible capacitance change on the time scale of 
several minutes. Unfortunately no further information is given, so that the results 
cannot be interpreted in relation to concentrations of the background electrolyte and 
the analyte, nor other physical and chemical environmental conditions (Newman et 
al., 1986). The methodology is based on the principle that for an electrolytic 
capacitor, the interfacial capacitance depends on the thickness and dielectric behavior 
of a dielectric layer on the surface of a metal (Gebbert et al., 1992).  
The capacitance and the sensitivity of the device are related to the thickness of 
the dielectric. The electric capacitance between two parallel plate separated a distance 
d is given by Eq. 1.1. 
 
 C = ɛ0ɛ A/d        Eq. 1.1 
  
 Where ɛ0 is permittivity of free space, ɛ is the dielectric constant of material 
between the plates, d is distance between two plates and A is the surface area. 
 
  Electrochemical immunosensors can be considered as electrolytic capacitors, 
with one “capacitor plate” represented by the charges accumulated at the antibody 
modified metal surface of the electrode covered with an insulator and the other 
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“plate” being represented by the Helmholtz layer of counter-ions in electrolyte. The 
binding of antigen to immobilized antibodies will, as shown in Figure 1.7, move the 
two constituting layers of the capacitance apart from each other, causing, in 
accordance with Eq. 1.1, the capacitance to decrease since the distance of the “plates” 
increase. The capacitance change between before and after antigen capture is 
concentration dependent and thus allows quantification of antigen. This type of 
capacitance measurements will be described in full detail later in Chapter II, Section 
2.3.2.3. 
 In order to make the capacitive immunosensor, the antibody has to be properly 
attached to the transducer with the boundary condition that the biological function 
(equal to the ability to conjugate with the corresponding antigen) is preserved. This 
process is commonly known as antibody immobilization. Proper immobilization is an 
important step in capacitive immunosensor since the electrode surface has to be 
equipped with the antibody and at the same time entirely electrically insulated. 
Different immobilization techniques have been developed and antibodies may be 
immobilized on capacitive sensors via the use of modified semiconductor surfaces 
(Barraud, Perrot, Billard et al., 1993; Bataillard, Gardies, Jaffrezic-Renault et al., 
1988), metal oxides surfaces (Gebbert, Alvarez-Icaza, Stoecklein et al., 1994), or self-
assembled monolayers (SAMs) of sulfur compounds on gold (Berggren and 
Johansson, 1997; Berggren, Bjarnason, and Johansson, 1998). 
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Figure 1.7  Representation of the dielectric layer in front of an antibody-modified 
gold electrode. One layer (“plate”) is the charged surface of the antibody modified 
metal electrode with an insulator itself and the second layer (“plate”) is formed by 
ions of opposite charge that accumulate at the electrolyte/electrode interface via 
electrostatic attraction (blue circle). The thickness of the dielectric layer (= distance of 
the two “plates”) increases when antigens binds to antibody and squeezes in between, 
causing the capacitance to decrease. A measured capacitance change thus is an 
indication of antigen capture, and the concentration dependence of the effect makes 
quantification of antigen possible. 
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 SAMs of alkane-thiols on gold turned into a versatile model system for 
electrochemists in the last decade as through clever design of bifunctional HS-(C)n-X 
compounds intentional electrode surface modification in a well-defined and 
reproducible way became accessible and opened elegant opportunities for the buildup 
of molecular architectures on this type of sensor surface (Schweiss, Werner, and 
Knoll, 2003). In particular, the simplicity of an automatic formation of a SAMs and 
the related ease of sulfur bond-based antibody immobilization made it an attractive 
strategy for achieving better control in the orientation and molecular organization of 
biomolecules at interfaces (Akram, Stuart, and Wong, 2004). 
 The stability of SAMs arises from the strong chemical absorption of the 
sulfur-atom on metal interfaces in combination with intermolecular interaction 
between the protruding alkyl chains (Wink, van Zuilen, Bult et al., 1997). The bond 
between sulfur and gold atoms is very strong and SAMs are thus stable in air, water 
and organic solvent at room temperature (Berggren and Johansson, 1997; Bain, Evall, 
and Whitesides, 1989; Chaki and Vijayamohanan, 2002). The SAMs technique is a 
simple way to obtain a reproducible and well-ordered layer suitable for further 
modification with antibodies, and improved detection sensitivity, speed, and 
reproducibility are the gains (Fu, Yuan, Tang et al., 2005). In electrolytes, self-
assembled monolayer on Au are usually quite stable in the potential window of -400 
to +1400 mV vs. SCE in dilute acidic solution, which is well suitable for applications 
in electrochemical sensing (Finklea, Avery, Lynch et al., 1987). 
 Thiourea (NH2CSNH2), a reasonably cheap thiol reagent with low 
environmental impact and strong adsorption on gold.  It has amino groups (R-NH2) 
that can be covalently coupled to -NH2 entities in the antibody protein structure via 
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exposure to the chemical cross-linker glutaraldehyde. The application of thiourea as 
starting layer for the formation of capacitive immunosensors has recently been 
introduced and the novel functional compound performed very well in the completed 
sensors with good reliability in the formation of the antibody-modified sensing layer 
and support of good analytical figures of merit for sensor operation in a flow 
injection-based capacitive immunosensing system
 
(Limbut et al., 2006a, b). Based on 
the good reported behavior of self-assembled thiourea monolayer as basis for 
capacitive immunosensors, this particular surface modification was the choice in this 
thesis for the establishment of the target YKL-40 and YKL-39 capacitive 
immunosensors. 
 
1.4  Thesis objectives 
 Main goal of this thesis was the development of capacitive immunosensors for 
the direct sensitive and selective detection of the chitinase-like proteins YKL-39 and 
YKL-40 using specific antibodies immobilized on a self-assembled thiourea 
monolayer on gold surfaces as analytical tool in a flow-based analysis system. Tasks 
included thorough performance tests with of the YKL-39/40 capacitive 
immunosensors for the determination of their corresponding analyte levels in model 
and clinical samples and a comparison with data from applications of commonly-used 
enzyme-linked immunosorbent assay (ELISA).   
The six major objectives of this research. 
1. To express and purify human YKL-40. 
2. To produce polyclonal antibodies specific for human YKL-40. 
3. To develop a capacitive immunosensor for human YKL-40. 
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4. To test the human YKL-40 capacitive immunosensor in clinical samples. 
5. To develop a capacitive immunosensor for human YKL-39. 
6. To test the human YKL-39 capacitive immunosensor in clinical samples. 
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1  Materials 
2.1.1  Chemicals and reagents 
  All chemicals reagent used were analytical grade. A protein A agarose column 
and HRP-conjugated anti-rabbit IgG were obtained from GenScript Inc., Piscataway, 
NJ, USA. The pQE-Tri System expression vector, a Ni-nitrilotriacetic acid (Ni-NTA) 
agarose column and Escherichia (E.) coli stain M15 (pREP) and DH5α were 
purchased from Qiagen Ltd., Manchester, UK. Ampicillin, phenylmethylsulphonyl 
fluoride (PMSF), imidazole and TritonX-100 were products of USB Corporation, 
Cleveland, OH, USA. Isopropyl thio-β-D-galactoside (IPTG), Freund's complete 
adjuvant, Freund's incomplete adjuvant, Tris–HCl, Tris-base and lysozyme were from 
Sigma Aldrich, St. Louis, MO, USA. 3,3′,5,5′-tetramethylbenzidine (TMB), the 
substrate for ELISA assays, was purchased from Invitrogen, Carlsbad, CA, USA. 
Glutaraldehyde, 1-dodecanethiol, potassium ferricyanide (K3[Fe(CN)6]), and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were purchased from Acros 
Organic, Bridgewater, NJ, USA. Protein concentrationswere measuredwith a Pierce
®
 
BCA Protein Assay kit from Thermo Scientific, Rockford, IL, USA. Skimmed milk 
powder was product of Himedia (Himedia Laboratories Pvt. Ltd., Mumbai, India). All 
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other basic chemical reagents (e.g. NaCl, KCl, Na2HPO4, KH2PO4, Urea, HCl, H2SO4 
and thiourea) were from Carlo Erba Reagents, Cornaredo (MI), Italy and unless 
otherwise mentioned were of analytical grade. Alumina slurries with a particle size of 
1 and 5 μm, as used for gold sensor surface polishing, were obtained from Metkon 
Instruments Ltd., Bursa, Turkey. A Hiprep 26/10 desalting column was supplied by 
GE HealthCare, Hatfield, UK and Vivaspin-20 ultrafiltration membranes came from 
Vivascience AG, Hannover, Germany. All aqueous solutions were prepared with 
purified water from a reverse osmosis-deionizing system (Cascada™ Lab Water 
Systems, PALL Life Science, Ann Arbor, MI, USA). Buffers were filtered through 
Whatman
®
 cellulose nitrate membrane with pore size 0.20 μm from GE HealthCare, 
Hatfield, UK. Fetal Calf Serum (FCS), Roswell Park Memorial Institute (RPMI-1640) 
medium, and Dulbecco’s Modified Eagle’s Medium (DMEM) were obtained from 
Gibco
®
 (Grand Island, NY, USA). Other chemicals and molecular reagents used but 
not listed here were purchased from a variety of suppliers. 
 
2.1.2   Instrumentation 
  ELISA analysis was performed using a Biochrom
® 
Anthos Multi Read 400 
Microplate Reader (Biochrom Ltd., Cambridge, UK). All electrochemical 
immunosensor recordings were made with an EA163 potentiostat and e-corder 410 
data acquisition device, from eDAQ, Denistone East, Australia. The system for flow 
injection-based sample measurements used a peristaltic pump (Miniplus
®
 3 from 
Gilson, Middleton, WI, USA), a manual injection valve (Biologic MV-6
®
 from Bio-
Rad, Hercules, CA, USA) and a three-electrode radial flow cell with customized 3-
mm-diameter gold disk electrodes (ALS Co., Ltd., Tokyo, Japan).  
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2.2   Methods 
2.2.1   Molecular biology 
2.2.1.1 Preparation of competent cells of E. coli strains DH5α and M15 (pREP)  
  E. coli from glycerol stock was streaked onto a Luria broth (LB, 10 g/L 
tryptone, 5 g/L yeast extract, 5 g/L sodium chloride) agar plate containing 50 μg/mL 
kanamycin and 100 μg/mL ampicillin for the M15 (pREP) stain or without antibiotic 
for the DH5α strain. A single colony was picked into 5 mL LB media containing 
antibiotics as listed above. The cells were grown at 37°C for 16-18 hr. with shaking at 
200 rpm. Then, 0.5 mL of starter culture was inoculated into 50 mL LB prepared in a 
250 mL flask and incubated at 37°C with shaking until the OD600 reached 0.5-0.6. The 
culture was cooled on ice for 15 min, then transferred to pre-cooled centrifuge tubes, 
and cell pellet was collected by centrifugation at 3,000 rpm for 10 min. Cells were 
gently and slowly resuspended with 10 mL of cold 0.1 M CaCl2 and placed on ice for 
20 min. The cells were centrifuged as before and resuspended with 0.5 mL of cold 0.1 
M CaCl2 and placed on ice for 1 hr. Finally, cold glycerol was added to the cells to the 
final concentration of 15%. Then, they were resuspended and 50 μL aliquots were 
stored in pre-cooled tubes at -80°C.  
 
2.2.1.2  Transformation of plasmid DNA into competent cells  
  Plasmid DNA (20 ng) was added into the 50 μL of competent cells, mixed by 
tapping and immediately place on ice for 30 min. The cells were heat shocked at 42°C 
for exactly 45 s and then immediately put on ice for 10 min. Then, 0.9 mL of LB 
medium was added into the cell mixture and the tube was incubated in a 37°C shaker 
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for 1 hr. Then, 100-200 μL of the cells were spread on an LB plate containing the 
appropriate antibiotics and incubated at 37°C overnight. 
 
2.2.1.3  Denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blot analysis. 
  SDS-PAGE was carried out following Laemmli (1970). Protein samples 
were prepared by mixing with 3X loading buffer (150 mM Tris-HCl, pH 6.8, 5% (v/v) 
of 2-mercaptoethanol, 6% (w/v) SDS, 30% (v/v) glycerol and 0.03% (w/v) 
bromophenol blue), and then boiled for 5 min. The samples will be centrifuged at 
12,000 rpm for 5 min, and then 10-15 μL supernatant is loaded onto 12% SDS-PAGE 
gel (3.345 mL of distilled water, 2.5 mL of 1.5 M Tris-HCl, pH 8.8, 4 mL of 30% 
acrylamide/bisacrylamide solution, 100 μL of 10% (w/v) SDS, 50 μL of 10% (w/v) 
ammonium persulfate, and 5 μL TEMED. The 4% stacking gel was prepared by 
mixing 3 mL of distilled water, 1.25 mL of 0.5 M Tris-HCl, pH 6.8, 0.67 mL of 30% 
acrylamide/bisacrylamide solution, 50 μL of 10% (w/v) SDS, 25 μL of 10% (w/v) 
ammonium persulfate, and 5 μL of TEMED) with a discontinuous Tris-glycine buffer 
system set in a Mini-PROTEAN
®
 3 cell (BioRAD). A constant potential of 120 V is 
applied across the SDS-PAGE gel for 1 hr. using Tris-glycine, pH 8.3, as a running 
buffer. After electrophoresis, the gel were stained with 0.025% coommassie brilliant 
blue R250 (40% methanol, 7% acetic acid) for 30 min, and then destained with a 
destaining solution (40% methanol, 7% acetic acid) until the background is clear. 
Molecular weights of proteins were estimated by comparing with the pink plus 
prestained protein ladder (GeneDirex, Taiwan) that contains 11 proteins that 
resolve in the range of 10-175 kDa. Whereas western blotting technique, after run 
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SDS-PAGE, then transfer proteins in the gel onto nitrocellulose membrane by semi-
dry transfer device (Trans-blot SD semi-dry cell transfer; Bio-Rad, Hercules, CA, 
USA). After transfer, incubate membrane in 5% skimmed milk in 1X PBS, pH 7.2 for 
one hour at room temperature. Add the primary antibody (anti-YKL-40 or anti-YKL-
39) to membrane and incubate 1-2 hr. at room temperature. Remove antibody solution 
and wash membrane three times for 5 min each with 0.1% Tween-20 in 1X PBS, pH 
7.2 (PBST) and then add Horseradish peroxidase conjugated-goat-anti-rabbit Igs 
(secondary antibody) to membrane and incubate for 1 hr. at room temperature with 
shaking. Remove antibody solution and wash membrane three times for 5 min each 
with PBST. Remove solution from the membrane. Apply chemiluminescent substrate 
reagent to cover all surface of the membrane. Incubate at room temperature for 3 min 
and detect the protein band by developing with X-ray film at various times, in dark 
room. 
 
2.2.1.4  Cell culture 
  All human cell lines were of American cell culture collection. Human T cell 
lines (Jurkat), human leukemic monocyte lymphoma cell line (U937) and human 
leukemia cell line (THP-1) were cultured in Roswell Park Memorial Institute (RPMI-
1640) medium, supplemented with 10% heat inactivated fetal calf serum (FCS), 40 
μg/mL gentamycin and 2.5 μg/mL amphotericin B in a humidified atmosphere of 5% 
CO2 at 37°C. Human embryonic kidney cells (293T) were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) with the condition as mentioned above. After 
cell passages of three times a week, the cells were collected, and washed three times 
with 1X PBS, pH 7.2  by centrifugation at 1,500 rpm for 5 min. Then 1x10
7
 cells were 
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lysed on ice for 30 min in 1 mL of lysis buffer (50 mM Tris-HCl, pH 8.2, 100 mM 
NaCl, 2 mM EDTA, 0.02% (w/v) NaN3, 1% (v/v) TritonX-100, 1 mM 
phenylmethylsulphonylfluoride (PMSF), 5 mM iodoacetamide, and 10 μg/mL 
aprotinin) at 4°C for 30 min. Clear lysate was collected by centrifugation at 13,000 
rpm, 4°C for 30 min, and used for further experiment. 
 
2.2.1.5  Expression and purification of recombinant YKL-40 in E. coli strain 
M15 (pREP) (bYKL-40) 
  E. coli strain M15 (pREP) competent cells were transformed with pQE-tri 
system plasmids that contained YKL-40 gene and cultured in 5 mL LB medium 
supplemented with ampicillin (100 µg/mL), incubated at 37°C, 200 rpm shaking. The 
overnight culture were diluted to a ratio of 1:100 with LB medium supplemented with 
ampicillin (100 µg/mL), and further grown at 37°C until OD600 reaches 0.6. The 
culture was pre-incubated at 25°C for 30 min, then isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM, and then 
the bacterial culture was incubated at 25°C for additional 16 hr. with 150 rpm 
shaking. With this protocol, the recombinant bYKL-40 was expressed in inclusion 
bodies. The IPTG-induced cells was harvested by centrifugation at 4,500 rpm at 4°C 
for 45 min. Cell pellet was kept at -80°C until used or re-suspended in lysis buffer (50 
mM Tris–HCl buffer, pH 8.0, containing 300 mM NaCl, 1 mM PMSF, 1.0 mg/mL 
lysozyme and 1% (v/v) TritonX-100) and then lysed on ice using a Sonopuls 
Ultrasonic homogenizer with a 6-mm diameter probe (50% duty cycle; amplitude 
setting, 20%; 30 s, 6 to 8 times). Cells debris was removed by centrifugation at 12,000 
rpm at 4°C for 30 min, while white pellet containing bYKL-40 was collected. The 
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insoluble protein was further solubilized 8 M urea, and cell pellet was removed the 
cell pellet by centrifugation at 12,000 rpm at 4°C for 60 min. Then, the 
solubilized/denatured bYKL-40 protein was further purified by Ni-NTA affinity 
chromatography run under gravity. To bind the His8-tagged proteins to the Ni-NTA 
resin, 5 mL of Ni-NTA agarose resin, which had been equilibrated with equilibration 
buffer, containing 8 M urea, was added to 40 mL of the solubilized protein extract and 
then gently shaken on ice for 1 hr. The protein-bound resin was washed with 10 
column volumes of equilibration buffer, followed by 5 column volumes of wash 
buffer 1 (10 mM imidazole in equilibration buffer) and 5 column volumes of wash 
buffer 2 (20 mM imidazole in equilibration buffer). Finally, the bound protein was 
eluted with elution buffer (250 mM imidazole in equilibration buffer). Fractions 
containing YKL-40 were pooled and then subjected to several rounds of membrane 
centrifugation using Vivaspin-20 ultrafiltration membrane concentrators (Mr 10000 
cut-off) for complete removal of imidazole. The purity of the purified YKL-40 was 
verified by SDS-PAGE and the final protein concentration was determined using the 
Pierce
®
 BCA Protein Assay kit by (Novagen, Darmtadt, Germany). 
 
2.2.1.6 Expression and purification of recombinant YKL-40 in 293T cells 
(mYKL-40) 
  293T cell line was cultured in DMEM medium, the day before transfection, 
500,000 cells of were seeded into 6 well in 3 mL of DMEM medium without 
antibiotics so that cells were 70-90% confluent at the time of transfection. For each 
transfection sample, prepare complexes as follows: (solution a) Dilute 2 µg of mYKL-
40/pCMV/hygro-His recombinant plasmid (Sino Biological Inc., Beijing, China) in 
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250 μL of DMEM medium without FCS and antibiotic, mix gently. (solution b) Mix 8 
μL of lipofectamine® 2000 with 250 μL of DMEM medium without FCS and 
antibiotic. Incubate for 5 min at room temperature. After that combine the diluted 
DNA (solution a) with diluted lipofectamine
®
 2000 (solution b) (total volume = 500 
μL). Mix gently and incubate for 20 min at room temperature. Then, add the 250 μL 
of complexes to each well containing cells and medium. Mix gently by rocking the 
plate back and forth. Incubate cells at 37°C in a CO2 incubator for 48 hr. and collect 
the supernatant that contain YKL-40 protein. Then, the culture supernatant was 
further purified by affinity chromatography on a Ni-NTA agarose column run under 
gravity. To bind the His10-tagged protein to the Ni-NTA resin, 25 μL of Ni-NTA 
resin, which had been equilibrated with equilibration buffer (50 mM NaH2PO4, 300 
mM NaCl, adjust pH to 8.0 using NaOH) was added to 10 mL of culture supernatant 
and then gently shaken on ice for 1 hr. The resin-bound protein was centrifuged at 
1,000 rpm for 5 min at 4°C, the supernatant was removed and then the protein-bound 
resin was washed with 1 mL of equilibration buffer, 1 mL of wash buffer 1 (10 mM 
imidazole in equilibration buffer) and 1 mL of wash buffer 2 (20 mM imidazole in 
equilibration buffer) repeat for each step of washing five times. Finally, the bound 
protein was eluted with elution buffer (250 mM imidazole in equilibration buffer). 
Fractions containing YKL-40 were pooled and follow by the buffer exchange to 1X 
PBS, pH 7.2 using dialysis bag (Standard RC tubing, MW cut-off 12-14 kDa, 
Spectrum Laboratories, Inc., CA, US) for removal of imidazole. The purity of the 
purified YKL-40 was verified by SDS-PAGE and the final protein concentration was 
determined using the Pierce
®
 BCA Protein Assay kit. 
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2.2.2   Immunology  
2.2.2.1 Polyclonal antibody production 
  YKL-40 polyclonal antibody production was carried out using in-gel protein 
method (Amero, James, and Elgin, 1988). Firstly, purified YKL-40 protein (20 to 25 
µg per well) was separated by 12% SDS-PAGE. Following the electrophoresis, the 
gel was stained with 0.025% coomassie brilliant blue R250 for 30 min, and then 
destained with destaining solution until the background was clear. After destaining 
thoroughly with distilled water for overnight, the YKL-40 band was excised from gel,  
homogenized with 250 µL of 1X PBS, pH 7.2 and then mixed with 250 µL of 
Freund’s complete adjuvant (Sigma, St. Louis, Mo, USA). The protein mixture was 
used to as immunogen by subcutaneous injecting into a female New Zealand white 
rabbit, 10 weeks age. The immunization was repeated twice every second week. 
Below is the work plan for polyclonal anti-YKL-40 antiserum production.  
  Week 0:  Collection of pre-immune serum (10 mL). 
  Week 1:  First immunization with ~ 100 μg of YKL-40 protein in Freund’s 
complete adjuvant. 
  Week 3:  First boosting with ~ 100 μg of YKL-40 protein in Freund’s 
incomplete adjuvant. 
  Week 4:  Second boosting with ~ 100 μg of YKL-40 protein in Freund’s 
incomplete adjuvant. 
  Week 5: Third boosting with ~ 100 μg of YKL-40 protein in Freund’s 
incomplete adjuvant. 
  Week 6:  Collection of blood serum (30 mL). 
  Week 7:  Collection of blood serum (30 mL). 
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  Week 8:  Collection of blood serum (30 mL). 
  Week 9:  Collection of blood serum (30 mL). 
  The blood serum was collected from the central ear artery with a 21-gauge 
needle. The blood serum was allowed to clot and retract at 4°C overnight, and the 
serum was retrieved by centrifugation at 4,500 rpm for 15 min. The titer of antiserum 
was determined by indirect ELISA and Western blotting.  
 
2.2.2.2  Purification of polyclonal antibody 
  The immunized serum was purified by affinity chromatography on a protein 
A agarose column run under gravity (GenScript Corporation, USA). Serum sample 
was diluted with Binding buffer (0.15 M NaCl, 20 mM Na2HPO4, pH 8.0) at a ratio of 
1:1 to ensure that proper ionic strength and pH are maintained for optimal binding, 
and further filtered through a 0.20 μm filter to remove cells. The diluted serum sample 
was applied onto protein A resin gravity column which was equilibrated with 10 
column volumes Binding buffer. Bound IgG resin was washed with 30 column 
volumes binding Buffer. Bond antibodies were eluted with 10 column volumes 
Elution Buffer (0.1 M glycine, pH 2.5) and were further immediately neutralized to 
pH 7.4 with 1 M Tris-HCl, pH 8.5 at a ratio of 1:10 volume of total eluted. The eluted 
fraction was then applied onto Hiprep 26/10 Desalting column (GE-Healthcare) for 
buffer exchanging to 1X PBS, pH 7.2. The purity of anti-YKL-40 was verified by 
SDS-PAGE. Antibody concentration was determined by Pierce
®
 BCA Protein Assay 
kit. Purified antiserum aliquots were stored at −40°C.  
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2.2.2.3  Characterization of anti-YKL-40 polyclonal antibody 
2.2.2.3.1  Determination of the antibody titers and specificity by western blotting 
  Titer and specificity of the anti-YKL-40 polyclonal antibody were 
determined by western blotting. Two micrograms of the purified YKL-40 was 
resolved on a 12% SDS-PAGE, and then electrophoretically transferred onto a 
nitrocellulose membrane by the semi-dry transfer blotting technique. After blotting, 
non-specific binding was blocked by incubation with 5% (w/v) skimmed milk in 1X 
PBS, pH 7.2 for 1 hr. at room temperature. The blocked membrane was rinsed once 
with 1X PBS, pH 7.2 before cutting into 6 strips, each 1 cm wide. Each strip was 
incubated for 1 hr. at room temperature with two-fold serial dilutions (1:5,000, 
1:10,000, 1:20,000, 1:40,000, 1:80,000, and 1:160,000) of anti-YKL-40 serum. Cross-
reactivity against other YKL-40 homologues, including YKL-39, AMCase and 
bacterial chitinase, was used to test antibody cross-reactivity. The antibody-antigen 
interaction was detected with HRP-conjugated goat-anti-rabbit IgG using the 
enhanced chemiluminescence method (Thorpe et al., 1985).  
 
2.2.2.3.2  Determination of the antibody titers and specificity by ELISA 
  For ELISA analysis, each well of a 96-well plate was loaded with 50 μL of 
YKL-40, YKL-39, AMCase or bacterial chitinase, each well contained 1 to 500 μg/L 
protein in 0.2 M sodium carbonate buffer, pH 9.6. The coated plated was incubated, 
overnight at 4°C. After that supernatant was discarded, and the loaded plate was 
blocked with 200 μL per well of 2% (w/v) skimmed milk in 1X PBS, pH 7.2 
(blocking buffer). After 1 hr. of incubation at 25°C, the treated plate was washed once 
with 300 μL per well of 0.05% (v/v) Tween-20 in 1X PBS, pH 7.2 (PBST). In a 
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routine, 50 μL of 15.6 μg/L anti-YKL-40 antisera (prepared in blocking buffer) was 
added to each well. The plate was incubated at 25°C for 1 hr., followed by 4 washes 
with PBST. HRP conjugated-goat-anti-rabbit IgG was added, incubated at 25°C for 1 
hr, followed by wash 5 times with PBST to remove the unbound antibody. To develop 
color after the peroxidase reaction, 100 μL of TMB substrate was added to each well 
after four washes. The reaction was then stopped by adding 100 μL of 1 N HCl 
solution. The intensity of the developed color was determined spectrophotometically 
using a microplate reader used at a wavelength of 450 nm. For titration experiments, 
the wells of a microtiter plate were treated with 50 μL of YKL-40 solution of various 
concentrations (2 fold-dilutions from 1 to 500 μg/L) with incubation overnight at 4°C. 
The remaining steps of ELISA were carried out as described above. 
 
2.2.3   Development of immunosensor specific for YKL-39/40 
  The desired capacitive immunosensor specific for the two human chitinase-
like proteins (YKL-39 and YKL-40) were developed by immobilizing the 
corresponding polyclonal antibodies against human chitinase-like proteins on the 
surface of gold working electrode using a self-assembled thiourea monolayer and a 
glutaraldehyde crosslinking strategy for protein surface anchoring. Detailed 
information on the antibody immobilization on gold electrodes and on the application 
of the YKL-39/40 immunosensors for capacitive antigen monitoring and 
quantification will be provided in the following sections. 
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2.2.3.1  Preparation of capacitive YKL-39/40 immunosensors 
  The capacitive immunosensors were result of a literature-known procedure 
that worked with a sequence of mechanical and electrochemical cleaning, self-
assembled thiourea monolayer formation and glutaraldehyde-assisted chemical 
antibody immobilization (Chaocharoen et al., 2015; Berggren et al., 2001; Berggren 
and Johannsson, 1997; Limbut et al., 2006a, b). In brief, gold electrodes (3-mm 
diameter, 99.9% purity) were very thoroughly polished on soft polishing pads that 
were soaked with alumina slurries of decreasing particle size (5, 1 and 0.5 micron, 
respectively). The sequential polishing steps were interrupted by intense water rinsing 
and, after final polishing, a 15 min ultrasonication in water.  Smoothened gold 
electrode surfaces dried in a stream of N2 gas before they were further 
electrochemically cleaned in a 0.5 M H2SO4 electrolyte with 25 repetitions of a 100 
mV/s potential scan from 0 to 1.5 V vs. Ag/AgCl reference electrode. Rinsing with 
deionized water and drying in a stream of N2 gas made the electrodes ready for the 
application of the immobilization chemistry. A cleaned gold electrode was actually 
immersed at room temperature for 24 hr into a 250 mM thiourea. This allowed the 
selected bifunctional thiol, it has sulfur and amino groups in the structure, thiol self-
assembled on the electrode disk via covalent Au-S bond formation; the amino groups 
remained to be untouched and, pointed off the surface, were the target for the 
following glutaraldehyde assisted crosslinking with equivalent entities in the antibody 
structure.  Thiourea-modified electrodes were thoroughly rinsed with deionized water 
to remove excess thiourea and then dried with N2 gas. Final step was the coupling of 
the antibody (either YKL-39 or YKL-40) to the primed gold electrode. Start was a 20 
min treatment with 5% (v/v) glutaraldehyde in 10 mM sodium phosphate buffer, pH 
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7.0. Rinsing with 10 mM sodium phosphate buffer, pH 7.0 removed excess 
glutaraldehyde. The amino groups of the self-assembled thiourea layer on the Au 
electrode got at this stage covalently linked to the glutaraldehyde molecules and, after 
being dried in a stream of N2 gas, the electrode was prepared for the last reaction, 
namely the exposure to antibody of choice and final -CHO/-NH2 crosslinking. To do 
so, 20 µL of 1 mg/mL antibody were placed on the surface of the Au electrode and -
CHO/-NH2 reaction was allowed to take place overnight at 4ºC. As a last step in the 
preparation, covalently antibody-modified electrodes were placed for 20 min in a 10 
mM ethanolic 1-dodecanethiol solution in order to cover remaining bare areas of the 
gold surface and create the well-insulated condition that is needed for success with a 
capacitive readout of antigen capture. Routinely, electrodes were kept at 4ºC in a 
closed box filled with nitrogen gas, when not used for measurements. 
  Success with gold electrode cleaning and stable antibody modification was 
checked via voltammetric tests in 5 mM solutions of potassium ferricyanide in 100 
mM KCl. Cyclic voltammograms of the aqueous Fe (III) redox species were recorded 
at the end of the each stage of electrode treatment with a scan range of  +0.7 to -0.2 V 
vs. Ag/AgCl reference electrode and a scan rate of 0.1 V/s. Judgments on the quality 
of particular steps in the electrode preparation were possible by  interpretation of the 
Fe (III) reduction current signatures, in terms of peak magnitude and position. 
 
2.3.2.2  The workstation for flow-based capacitive YKL-39/40 immunosensing 
  All measurements of YKL-39 and YKL-40 with a capacitive readout of 
antigen-antibody affinity binding were carried out in a flow injection system as 
illustrated on Figure 2.1. Working electrode in the electrochemical flow cell of the 
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arrangement was the antibody-modified gold electrode while the stainless steel tube 
liquid outlet of the flow-through electrochemical cell was connected to the 
potentiostat as the counter electrode. Placed opposite of the detecting disk of the 
immunosensor was a common Ag/AgCl reference electrode. The three-electrode 
electrochemical cell was operated by a computer-controlled potentiostat (EA 
163/ED410, eDAQ, Australia), which was responsible for potential application, 
current measurements, and timely data acquisition and storage.  
 
 
Figure 2.1 Illustration of the equipment used for flow injection-based capacitive 
YKL-39/40 immunosensing. 
 
2.3.2.3  YKL-39/40 measurements with capacitive YKL-39/40 immunosensor 
  The apparatus for capacitive YKL-39 and YKL-40 capacitive 
immunosensing has been detailed in the previous section. The capacitance of the 
electrode surface used a signal for analyte determination and, upon calibration, 
quantification, was computed from the current response of the corresponding 
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immunosensors induced by repetitively applied potential steps of 50 mV and a few ms 
length. For the type of sensors used here for analysis, the current actually decays 
exponentially and the drop can mathematically be expressed via Eq. 2.1:  
 
 i(t) = E/Rs exp (-t/RsC) Eq. 2.1   
  
  where i(t) is the current in the circuit between the counter and working 
electrode as a function of time, E the potential applied to the immunosensor surface 
vs. the Ag/AgCl reference electrode, Rs the dynamic resistance of the immobilization 
layer, t the time that elapsed after the potential step was applied, and C is the total 
capacitance measured at the capacitive immunosensor electrode/solution interface. 
Taking the logarithm of Eq. 2.1 leads to 
 
 ln i(t) = ln E/Rs – (1/RsC) t Eq. 2.2   
  
  The value of the potential amplitude is known and the value of the y-
intercept is provided by the software used to generate the linear least-square fitting of 
ln i(t) versus t. Accordingly, Rs, can be computed and the obtained value further used 
to calculate  the capacitance from the slope of the regression line. In a typical 
analytical trial, the potential pulses were executed once every minute while the 
running buffer went through the flow cell and the capacitance values, extracted from 
the acquired current traces as described above, were plotted as function of time. When 
a sample solution with analyte is injected into the flow line, the YKL-39 or YKL-40 
molecules move downstream towards the electrochemical flow cell and the capacitive 
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immunosensor, where binding to the immobilized antibody happens on the gold 
electrode surface. As outlined earlier, the antigen capture is causing a decrease in 
capacitance; however, a stable value is reached at the point of maximum capture for a 
given concentration of analyte. The induced change in capacitance due to the antigen 
binding is gained by subtracting the capacitance after the binding events from its 
value before the binding (Chaocharoen et al., 2015; Berggren et al., 2001; Berggren 
and Johannsson, 1997 and Limbut et al., 2006a, b). Since capacitance change is 
proportional to the concentration of antigen, calibration curves can be constructed in 
calibration trials and later used for analyte quantification in model or real samples 
quantification trials. 
 
2.3.2.4  Parameter optimization YKL-39/40 immunosensing 
  All experimental parameters affecting the performance of the capacitive 
immunosensor were looked at and optimized to yield optimal analytical performance. 
Evaluated were type and concentration of regeneration solution, type of running 
buffer, pH of running buffer, concentration of running buffer, sample volume and 
flow rate. Optimization measurements were performed in triplicate by changing the 
variable under inspection while keeping all others fixed. When an optimum condition 
for the particular parameter was identified, the next parameter was made subject of 
optimization. The starting conditions for the optimization trials are shown in Table 
2.1. The selection of the optimal value for a certain parameter took a good balance 
between the sensitivity of the measurement and the analysis time for individual 
samples into account. 
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Table 2.1  Starting operational conditions. 
Parameter Options 
1. Type of regeneration solution low pH: HCl 
2. pH of regeneration solution pH 1.0 
3. Type of buffer sodium phosphate buffer 
4. pH of buffer pH 7.0 
5. Concentration of buffer 10 mM 
6. Sample volume 200 µL 
7. Flow rate 100 µL/min 
 
2.3.2.4.1 Choice of the optimal type of the regeneration solution 
  One important issue for success with qualitative and quantitative 
immunosensor analysis is whether the surface can after exposure to one antigen 
binding run be regenerated without significant loss of activity (Thévenot, Toth, Durst 
et al., 2001). Ideally, the regeneration of the working electrode should disrupt all 
antibody/antigen conjugates without adversely affecting the activity of the covalently 
immobilized antibody molecules and should also not destroy the self-assembled 
thiourea monolayer that provides the firm antibody bond to the gold surface. Gentle 
but effective regeneration allows immunosensor surfaces to be reused for 
quantification trials many times, saving both time and money (van der Merwe, 2000).  
  Following suggestions from published reports, the regeneration solutions 
tested in this work were divided into three categories, namely a high ionic strength 
solution (Pei, Cheng, Wang et al., 2001), a low pH solution (Chou, Hsu, Hwang et al., 
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2002), and high pH solution (Park, Kim, and Kim, 2000). The particular choices were 
actually 1 M NaCl or 1 M KCl (high ionic strength), Glycine/HCl pH 2.5 and HCl 
solution of pH 1.0 or 2.0 (low pH) and 5 mM or 50 mM NaOH (high pH). 
  Using the conditions 3 – 7 in Table 2.1 for other parameters than the type of 
the regeneration solution, small aliquots of a standard solution of the two human 
chitinase-like proteins were injected in course of the optimization trials into the 
capacitive immunosensor system and via the continuous flow of buffer transported 
into the flow cell of the detection system. Upon arrival, binding between the antigens 
and their corresponding immobilized antibody happened and caused the analytically 
relevant decreases in sensor capacitance. The different regeneration solution were 
then affected and used to break the antigen-antibody bond and force antigen to be 
flushed away in the flowing stream of the running buffer. A good regeneration 
solution was expected to let the sensor capacitance return to baseline level (the one 
before sample injection) in order to prepare the sensing tool for the next sample 
injection (Figure 2.2). An optimal regeneration solution would reproducibly 
reestablish the starting sensors surface condition by removing all captured antigen and 
restoring the original capacitance signal of the modified electrode before any antigen 
exposure effectively. The optimum regeneration solution was selected by considering 
the quality of the restored activity of modified electrode after regeneration. The 
percentage of residual activity is calculated from the capacitance change (∆C) 
resulting from the binding between antigen-antibody before (∆C1) and after 
regeneration (∆C2), as be described by Figure 2.2 and Eq. 2.3. Based on this 
definition, an ideal 100% restored activity refers to the situation where the 
capacitances of the immunosensor before sample injection and after regeneration were 
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absolutely the same. However, the regeneration was capable to restore the capacitance 
of the immunosensor surface to values above 90%, the binding efficiency can be 
considered as suitable (van der Merwe, 2000). Chosen of course for the analytical 
applications to the quantification of model and real samples here was the regeneration 
buffer with the highest value of the percentage of restored activity. 
 
 % restored activity = (∆C2/∆C1) x 100 Eq. 2.3 
 
 
Figure 2.2  A schematic diagram showing the capacitance change caused by binding 
between antigen and antibody following an YKL-39/40 protein sample injection. 
Injection of regeneration solution removes bound antigen from antibodies 
immobilized on gold electrode surface. When the base-line signal is recovered a new 
analysis cycle can be applied. 
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2.3.2.4.2  Choice of the optimal pH of the regeneration solution 
  The regeneration conditions could affect the performance and the lifetime 
of completed immunosensors because the antigen-antibody conjugation has to be 
broken and, as side effect, the antibody bond to the self-assembled thiol layer and/or 
the attachment of the thiol layer to the gold electrode surface may be weakened and/or 
even destroyed, too. In addition to the type of regeneration solution also the best level 
of acidity (pH) of the regeneration solution was tested in order treat in gentle but 
effective way with the reach of high percentage of restored activity. Tested here were 
HCl solutions with a pH of 3.0, 2.5, 2.0, 1.5, and 1.0. 
 
2.3.2.4.3  Choice of the optimal type of running buffer 
  It is essential to find the best type of the running buffer solution that is 
continuously guided through the electrochemical flow cell of the capacitive 
immunosensor system. Based on experiences reported by others for similar 
immunosensing schemes, the buffers that have been explored here included 10 mM of 
sodium phosphate buffer, 10 mM of HEPES buffer and 10 mM Tris-HCl buffer at pH 
7.0 (Loyprasert, Thavarungkul, Asawatreratanakul et al., 2008). Measured in the trials 
were the concentration-dependent responses of the YKL39/40 protein-modified gold 
electrodes to their corresponding analyte levels over a range of 1 ng/L to 100 mg/L. 
The sensitivity (slope) of the linear part of plots between capacitance change and 
logarithm of trialed antigen concentration was used as guiding criteria for the 
selection of the most suitable running buffer, which was then further optimized in 
terms of pH and ionic strength (Bezerra, de Lima Filho, Montenegro et al., 2003). 
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2.3.2.4.4  Choice of the optimal sample volume and flow rate 
  In the applied flow injection-type of YKL-39/40 protein analysis the 
volume of the sample that was injected into the stream of running buffer and also the 
flow rate for the running buffer were expected to have an effect on the quality level of 
the analyte quantification. Larger volumes would expose the sensor in a measuring 
run to more antigen molecules and saturation of the limited number of antibody 
entities may have been reached at lower concentration; variation of the flow rate 
would, on the other hand, affect the time available for the formation of the 
antibody/antigen conjugation. Both mentioned parameter would logically affect the 
linear range and/or sensitivity of the chosen detection scheme. Test trials were thus 
executed with sample injections ranging from 50, 100, 150, 200, 250, 300 to 400 µL 
and with flow rates of 50, 100, 150, 200, 300 and 400 µL/min. 
 
2.3.2.4.5  Summary of the performed optimization trials 
  The parameters to be optimized and the explored settings are summarized 
in Table 2.2. With the optimal parameter applied, the analytical performance of the 
system was evaluated and the limit of detection, linear range, sensitivity, specificity 
and reducibility for both the YKL-39 and YKL-40 capacitive immunosensor analysis 
was assessed.  
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Table 2.2  Target parameters for human chitinase-like proteins immunosensor 
optimization trials. 
Parameter Options 
1. Type of regeneration solution high ionic strength, low pH, high pH 
2. pH of regeneration solution pH 1.0, 1.5, 2.0, 2.5, 3.0 and 3.5 
3. Type of running buffer 
10 mM of sodium phosphate buffer, pH 7.0 
10 mM of HEPES buffer, pH 7.0 
10 mM of Tris-HCl buffer, pH 7.0 
4. pH of running buffer pH 6.0, 6.5, 7.0, 7.5, and 8.0 
5. Concentration of running buffer 5, 10, 25, 50, and 100 mM  
6. Sample volume 50, 100, 150, 200, 250, 300 and 400 µL 
7. Flow rate 50, 100, 150, 200, 300 and 400 µL/min 
 
2.3.2.5  Stability and selectivity tests with YKL-39/40 immunosensors 
  All organic, biological and other materials used for sensor construction may 
be prone to deterioration with time, especially when used in continuous flow of 
measuring buffer and with repetitive changes of exposures to running and 
regeneration buffers and sample solutions. Degradation (denaturation) is through 
environmental stress is obviously a major risk for the biological protein (antibody) 
component of the employed immunosensor and limited sensor lifetimes may thus be 
likely and would call for frequent sensor  replacements (Eggins, 1996). 
  Under identified optimum analysis condition the stability of immobilized 
electrode was studied by repetitive injections of standard solution of the two targeted 
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YKL-39/40 proteins into the immunosensor system and sequences of detection and 
sensor regeneration. Identified and used as hint of the sensor stability was the number 
of injections that could be done with the response of the immunosensor system 
remaining at a percentage of restored activity above 95%.  
  Selectivity tests were carried out to get an idea how reliably the target 
analytes could be detected in the presence of possibly interfering species that are 
structurally and/or chemically similar to the proteins of interest. Relevant 
interferences for this work were other members of the family GH-18 proteins, namely 
YKL-39 (for YKL-40 analysis), YKL-40 (for YKL-39 analysis), and AMCase (for 
both analyses). Standard solutions of YKL-39, YKL-40 and AMCase with 
concentrations of 1 ng/L to 100 mg/L were analyzed in triplicate with the proposed 
methodology in the capacitive immunosensor system, under the optimum conditions. 
Obtained calibration curves of each protein were plotted and compared.  
 
2.3.2.6  Limit of detection (LOD) 
  The limit of detection is defined as the amount or the content of an analyte 
corresponding to the lowest measurement signal which with a certain statistical 
confidence may be interpreted as indicating that the analyte is present in the 
solution/analytical sample, but not necessarily allowing exact quantification (AOAC, 
2004). Limit of detection can be calculated using follow equation: 
 
 LOD = (3 x SDb)/m                                          Eq. 2.4 
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  where LOD is limit of detection, SDb is the standard deviation of 20 
measurement of blank results and m is the slope of the calibration curve.  
  The running buffer was injected into capacitive immunosensor system for 
twenty times under the optimum conditions. The standard deviation was calculated. 
The slope of the calibration curve obtained from the injection of standard solution of 
YKL-39/40 at concentration between 0.1 µg/L and 1 mg/L into the capacitive 
immunosensor system in triplicate under the optimum conditions. The limit of 
detection was then calculated using Eq. 2.4. 
 
2.3.2.7  Determination of YKL-39/40 in model and clinical samples 
 To demonstrate the use of the developed capacitive immunosensor, the 
system was tested for model and clinical samples. The latter were for YKL-40 trials 
derived from blood samples of a healthy person and breast cancer and glioblastoma 
patients and for YKL-39 represented the synovial fluids of people with recognized 
appearance of osteoarthritis. All samples were determined by the capacitive 
immunosensor system and, for comparison, via application of the common ELISA 
technique. 
 
2.3.2.7.1  Model samples 
  To demonstrate the quality of the established YKL-39/40 capacitive 
immunosensing in a flow injection system, standard solutions of the two proteins 
were injected at various but known concentrations and determined with the scheme 
operated under optimum conditions. Prior to triplicate sample analysis, the calibration 
curves were prepared as plots of the capacitance change versus log of the analyte 
 
 
 
 
 
 
 
 
53 
 
concentration. The value of the capacitance change for a particular sample was used 
to compute their protein content from the predetermined calibration curve.  This 
allowed calculation of the percentage of recovery of analyte by the follow equation 
Eq. 2.5: 
 
 Recovery (%) = (CFound / CAdded) x 100 Eq. 2.5 
 
2.3.2.7.2  Clinical samples 
  For YKL-40 capacitive immunosensors, a set of clinical blood samples and 
two types of cell lysates were analysed under optimum conditions for their relevant 
protein content. The blood serum came actually from 4 healthy persons (in the 
following labeled as H1-H4), 5 breast cancer patients (in the following labeled as B1-
B5), and 4 Glioblastoma patient (in the following labeled as G1-G4) while cell lysates 
were from THP-1 and 293T cells. Prior to the triplicate analytical immunosensor and 
ELISA trials, serum samples were routinely diluted 10 times with the standard 
running buffer to reduce the matrix effect. The change in the capacitance of particular 
samples was used to calculate the concentration of YKL-40 from predetermined 
calibration curves. Compared were the blood serum and cell lysate levels of YKL-40 
from the immunosensor measurements with the outcome of the ELISA. 
 For YKL-39 capacitive immunosensors, the clinical samples and cell lysate 
that were tested under optimum conditions included four synovial fluids from 
osteoarthritis patient, a Jurkat cell lysate, a U937 cell lysate and a 293T cell lysate. 
All samples were in a parallel approach also inspected via an ELISA. Prior to 
triplicate quantification trials, the serum samples were diluted 10 times with running 
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buffer to reduce matrix effects and signal disturbance by other (proteins) species. The 
capacitance change of a particular sample was translated into an analyte concentration 
via calibration curve utilization. Values from the electrochemical YKL-39 screen 
were compared with the ones from the ELISA. 
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CHAPTER III 
RESULTS  
 
3.1  Capacitive immunosensor for detection of bYKL-40 
3.1.1 Expression and purification of YKL-40 in bacteria system (bYKL-40) 
  The full-length YKL-40 DNA was cloned into pQE-Tri System expression 
vector, which was ready to be expressed in E. coli strain M15 (pREP). The 
recombinant protein was expressed with the 21-amino acid N-terminal signal 
sequence attached, to aid protein targeting to the bacterial cell envelope and His8-
tagged at C-terminal. The bYKL-40 with signal peptide contains 381 amino acid 
residues and has a predicted MW of 42,338 Da. 
 Recombinant YKL-40 was expressed in E. coli strain M15 (pREP). Induction 
for 16 hr. with 0.5 M IPTG, cell pellet was collected and bYKL-40 was extraction by 
lysis buffer (Figure 3.1, Lane 1), the bulk of the induced bYKL-40 was insoluble that 
suggest the bYKL-40 was present in inclusion bodies. The insoluble fraction further 
solubilized with 8 M urea that fraction were contained bYKL-40 (Figure 3.1, Lane 2). 
12% SDS-PAGE analysis revealed several protein bands. To obtain highly purified 
bYKL-40 for antibody production and immunosensing preparation, the soluble 
bYKL-40 fraction was further purified by Ni-NTA affinity column. Figure 3.2 shows 
the 12% SDS-PAGE of the purified protein, which migrated as a single band around 
40 kDa (Lane 5), consistent with molecular mass expected for bYKL-40 lacking the 
20 amino-acid signal peptide and has a predicted MW of 40,488 Da. 
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Figure 3.1  SDS-PAGE analysis of bYKL-40 expression. Lane M, protein marker; 
Lane 1, bYKL-40 expression in cell pellet extracted with lysis buffer; Lane 2, YKL-
40 expression in cell pellet extracted with 8 M urea.  
 
 
Figure 3.2 SDS-PAGE analysis of bYKL-40 purification by Ni-NTA agaroes 
column.  Lane M, protein marker; Lane 1, soluble bYKL-40 fraction; Lane 2, Flow 
though; Lane 3, wash fraction with 10 mM imidazole; Lane 4, wash fraction with 20 
mM imidazole; Lane 5-7, eluted fractions with 250 mM imidazole. 
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3.1.2   Production and characterization of bYKL-40 polyclonal antibody 
 Purified bYKL-40 protein was used for the production of bYKL-40 polyclonal 
antibody. The polyclonal anti-bYKL-40 antiserum and antibody titers were 
determined by western blot assay (Figure 3.3). The polyclonal anti-bYKL-40 
antiserum reacted strongly with the bYKL-40 target protein at dilutions up to 
1:80,000 and a faint signal was detectable even at 1:160,000 dilutions. In contrast, no 
signal was detected from the pre-immune serum, even at the highest concentration 
tested (1:5,000 dilutions). Evaluations of cross-reactivity against other members of 
GH-18 were tested by western blot assay at 1:40,000 dilutions of polyclonal anti-
bYKL-40 antiserum. Western blots analysis (Figure 3.4A and B) revealed no 
interaction of the polyclonal anti-bYKL-40 antiserum with YKL-40 homologues, such 
as YKL-39, AMCase and chitinase A. These results confirming that polyclonal anti-
bYKL-40 antiserum was specific for bYKL-40.  
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Figure 3.3 Polyclonal anti-bYKL-40 antiserum titer. (A) 12% SDS-PAGE, 
coomassie-blue stained:  Lane 1, 2 μg of purified bYKL-40. (B) bYKL-40 protein 
detected by westen blot assay with the polyclonal anti-bYKL-40 antiserum (left-hand 
panel). Lane M, standard protein markers; Lane 1–6, 2 μg of purified bYKL-40 
detected with various dilutions (1:5,000, 1:10,000, 1:20,000, 1:40,000, 1:80,000 and 
1:160,000) of polyclonal anti-bYKL-40 antiserum. The same dilutions of pre-immune 
serum were used as negative control (right-hand panel). 
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Figure 3.4  Specificity of polyclonal anti-bYKL-40 antiserum. (A) Coomassie-blue 
stained 12% SDS-PAGE. (B) Immunoblot with polyclonal anti-bYKL-40 antiserum 
(1:40,000 dilution); pre-immune serum was used as a negative control (not shown). 
Lane 1, purified bYKL-40 (1.2 μg); Lane 2, YKL-39 (3.2 μg); Lane 3, AMCase (2.9 
μg); Lane 4, human serum (231 μg) and Lane 5, chitinase A (10.4 μg). 
 
  The polyclonal anti-bYKL-40 antiserum was fractionated by affinity 
chromatography using protein A agarose column run under gravity. SDS-PAGE 
analysis (Figure 3.5A) showed the purity of the anti-bYKL-40 polyclonal antibody, 
and confirmed that it was a protein A-specific IgG isotype. The immunoglobulin 
migrated abovethe 130 kDa marker under non-reducing condition (Figure 3.5A, Lane 
2), while reducing condition the sample produced two protein bands, of about 55 kDa 
and 22 kDa (Figure 3.5A, Lane 1), as expected for IgG (heavy chain; 50 kDa, light 
chain; 25 kDa) and whole molecule; 150 kDa. In Western blot analysis the purified 
nti-bYKL-40 polyclonal antibody reacted strongly with bYKL-40 down to 0.175 
mg/L, whereas the pre-immune serum showed no reaction (Figure 3.5B). 
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Figure 3.5  Purified anti-bYKL-40 polyclonal antibody. (A) SDS-PAGE analysis of 
purified anti-bYKL-40 polyclonal antibody:  Lane 1, under reducing condition; Lane 
2, non-reducing condition: coomassie-blue stained gel. (B) Antibody titers against 
bYKL-40 (2 μg): Lane M, standard protein markers; Lane 1–6, serial dilutions of the 
purified antibody to 2, 1, 0.500, 0.250, 0.175 and 0.078 mg/L, respectively (left-hand 
panel). Unfractionated pre-immune serum was used as a negative control (right-hand 
panel). 
 
  Cross-reactivity of the purified anti-bYKL-40 polyclonal antibody with related 
proteins was tested by indirect ELISA technique. Figure 3.6 shows binding of purified 
anti-bYKL-40 polyclonal antibody (50 μL, 15.6 μg/L) to bYKL-40 (curve a); the 
hyperbolic plot of the interaction signal with increasing antigen load in the microtiter 
plate well was characteristic of a specific interaction. With YKL-39 (curve b), 
AMCase (curve c) and chitinases A (curve d), no significant signal was obtained. The 
binding of each antigen was further tested with a fixed antigen load (50 μL, 125 μg/L) 
and constant anti-bYKL-40 polyclonal antibody (50 μL, 15.6 μg/L). A summary of 
this test is shown in Table 3.1. The signal for bYKL-40 was about 11-, 12.5- and 50-
fold larger than that for YKL-39, AMCase and chitinases A, respectively.  
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  The ELISA showed a linear range from 2.5 to 125 μg/L (Figure 3.6, inset). 
The linear regression equation is y = (0.008±0.001) x + (0.101±0.005) and correlation 
coefficient was 0.997. The lower limit of detection was 2.5 μg/L. 
  These results confirmed that the purified anti-bYKL-40 polyclonal antibody 
was highly specific for bYKL-40 target protein and thus suitable for use in bYKL-40 
capacitive immunosensor based flow injection system. 
 
 
Figure 3.6  bYKL-40 ELISA technique. Binding of purified anti-bYKL-40 
polyclonal antibody (50 µL, 15.6 µg/L) to different concentrations of surface-attached 
bYKL-40 related proteins: bYKL-40 (a); YKL-39 (b); AMCase (c) and chitinases A 
(d). Inset shows the calibration curve of bYKL-40 obtained from the ELISA 
technique. 
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Table 3.1  Interaction of bYKL-40 and its homologues with purified anti-bYKL-40 
polyclonal antibody. 
 A450** Reactivity*** 
bYKL-40* 1.17±0.03 1.00 
YKL-39* 0.10±0.01 11.63 
ChiA* 0.02±0.02 54.05 
AMCase* 0.09±0.01 12.41 
   * ELISA used a well load of 50 µL of 125 µg/L antigen     
   and 50 µL of 15.6 µg/L antibody aid affinity testing. 
** (A450) is the absorbance at wavelength of 450 nm. 
    Values are averages of triplicate measurement. 
*** Values normalized against bYKL-40. 
 
3.1.3   Capacitive bYKL-40 immunosensing 
3.1.3.1  Preparation of the capacitive bYKL-40 immunosensors 
  For capacitive immunosensors the insulating property of the self-assembled 
monolayer on the electrode surface is of vital importance. To investigate the gradual 
change of the electrical conductivity a bare gold disk electrode in course of the 
transition into a bYKL-40 capacitive immunosensor via thiol layer placement and 
subsequent covalent antibody immobilization cyclic voltammetry measurements were 
performed at different stages of the electrode modification in a 5 mM 
K3[Fe(CN)6]/0.1 M KCl  solution at a scan rate of 0.1 V/s vs. Ag/AgCl reference 
electrode, with the voltage varied from +0.7 to -0.2 V. The acquired collection of 
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voltammograms of such an electrode test trial is shown in Figure 3.7. At the clean 
gold disk electrode surface (curve a), the redox compound produced the expected pair 
of cathodic and anodic current peaks that relate to the reduction of Fe (III) to Fe (II) in 
the forward potential scan and subsequent re-oxidation of the Fe (II) to Fe (III) in the 
reverse potential scan. The magnitude of the two redox peaks decreased considerably 
upon placement of the self-assembled layer of thiourea since the molecular electrode 
coating is non-conductive and block the electron-transfer interaction of the Fe (III) in 
the solution with the charged gold disk (curve b). When glutaraldehyde was allowed 
to react with the amine groups of the thiourea and then anti-bYKL-40 was linked 
covalently on the electrode via reaction with of surface-bound remaining aldehyde 
groups with amine groups in the antibody structure, the insulating property of the gold 
electrode surface further decreased for the same reason as in the initial step of thiol 
monolayer formation (curve c and d, respectively). Finally, the modified electrode 
surface was exposed to a short treatment with 1-dodecanethiol in order to let this 
small thiol cover any still uncovered gold surface via self-assembly and establish 
complete insulation; evidence for the gain of a well-insulated bYKL-40 modified gold 
disk electrode (“the bYKL-40 capacitive immunosensor”) it that the current peaks 
virtually disappear fully (curve e). 
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Figure 3.7  Cyclic voltammograms of a gold electrode at various surface conditions. 
(a) clean (b) coated with a self-assembled thiourea monolayer, (c) after glutaraldehyde 
exposure of the thiourea film, (d) after anti-bYKL-40 bonding to the glutaraldehyde-
treated thiourea film and (e) after final treatment with 1-dodecanethiol. 
 
3.1.3.2  Parameter optimization for capacitive bYKL-40 immunosensing 
  The experimental parameters possibly influencing the performance of the 
bYKL-40 capacitive immunosensor included the type and pH of the regeneration 
solution, the type, concentration and pH of the running buffer, the injected sample 
volume and the flow rate, and they were all optimized to reach a satisfactory level of 
YKL-40 in model and real samples.  In each optimization test the capacitance changes 
of bYKL-40 capacitive immunosensors, following either individual or sequential 
multiple injections of 10 µg/L of bYKL-40 were evaluated as earlier described 
through an analysis of the recorded current response to ms-long potential steps. All 
measurements were executed in triplicate, with one parameter varied while the others 
ones were fixed. The starting operational conditions for the optimization trials are 
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shown in Table 2.1, Chapter II, Section 2.3.2.4. The following sections present the 
results of the parameter optimization, starting with the adaptation of the regeneration 
buffer and finishing with an adjustment of the flow rate.  
 
3.1.3.2.1  Optimization of the regeneration solution  
  Injection of 10 µg/L of standard bYKL-40 solution caused antigen 
conjugation to antibody on the sensor surface, producing a capacitance change. The 
modified surface had to be regenerated by the removal of bound bYKL-40 before the 
measurement of the next sample was possible. Since the affinity binding of bYKL-40 
and immobilized anti-bYKL-40 is of non-covalent nature the complex was liable to 
dissociation through exposure to a regeneration solution that was in support of bond 
weakening and release of antigen that then could be flushed away by the stream of the 
buffer. The efficiency of the tested regeneration solutions was determined by a 
calculation of a restored activity of the immobilized anti-bYKL-40, as it was 
described in Eq. 2.3 in Chapter II, Section 2.3.2.4.1. 
  Three types of regeneration solutions were studied including neutral 
solutions of high ionic strength (1 M KCl, 1 M NaCl) or high (5 or 50 mM NaOH) 
and low pH (50 mM glycine/HCl buffer, pH 2.5 and HCl solution, pH 1.0). The 
results in terms of the gained clearance of the antibody from bound antigen are for the 
set of regeneration tests shown in Figure 3.8. Treatment of used immunosensors with 
neutral solutions of high ionic strength (1 M KCl, 1 M NaCl) gave actually the lowest 
percentage of restored activity (24.5±2.1 and 12.4±1.3, respectively) and high pH (5 
or 50 mM NaOH) produced rather low percentage of restored activity values 
(30.3±0.6 and 40.7±0.1, respectively), too. Better was regeneration in acidic 
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regeneration solutions such as 50 mM glycine/HCl buffer, pH 2.5 and HCl solution, 
pH 1.0. Here percentages of restored activity were 59.1±1.4 and 67.5±0.2, 
respectively. Accordingly, regeneration with HCl solution of pH 1.0 was the most 
effective treatment because it offered the highest percentage of restored activity. 
 
 
Figure 3.8  Efficiency of different types of regeneration solutions. Percentage of 
restored activity is an expression that scales the amount of immobilized bYKL-40 
antibody that got released from bYKL-40 antigen that had been captured in course of 
a measurement cycle; the higher the percentage of residual activity, the more antibody 
was freed and successfully primed for capturing antigen again in the next analytical 
sample injection run. 
 
  The effect of pH of HCl solution was then studied for values of 1.0, 1.5, 
2.0, 2.5 and 3.0. The percentage of restored activity increased from 80.1±0.9 to 
99.4±0.5 when the pH was decreased from 3.0 to 2.5 (Figure 3.9). At a pH lower than 
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2.5, the percentage of restored activity decreased, which may be because of a 
destructive impact of such a strong acid on either the self-assembled thiourea 
monolayer or the antibody, or both. Based on the above, the HCl solution, pH 2.5 
offered the best regeneration with the recovery of antibody approaching an almost 
ideal 100%. This solution was thus used as the regular regeneration solution in all 
subsequent optimization trials and all other analytical bYKL-40 quantifications. 
 
 
Figure 3.9  The influence of the pH of the HCl regeneration solution on the 
efficiency of removal bYKL-40 from anti-bYKL-40 on a thiol-coated gold electrode. 
 
3.1.3.2.2  Optimization of the type of running buffer 
  The running buffer in the flow analysis system is at the same time the 
electrolyte in the electrochemical flow cell during the potential step-based capacitance 
measurements. It was therefore expected that the nature of the running buffer would 
affect the quality of a capacitive signal generation. Three types of running buffer 
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solutions, each with pH 7.0 and 10 mM of buffer concentration were tested as the 
constantly flowing liquid in the tubes of the flow system, namely sodium phosphate, 
HEPES and Tris-HCl buffers. A look at the sensitivity (slope) of plots between 
capacitance change in response to antigen injections and the logarithm of its 
concentration in the linear range (0.1 µg/L to 1 mg/L, Figure 3.10) showed that 10 
mM sodium phosphate buffer, pH 7.0 provided the highest sensitivity value and, for 
given injections, the largest specific capacitance changes. Therefore this type of 
buffer was used as the standard running solution for all work with the bYKL-40 
capacitive immunosensors. 
 
 
Figure 3.10  The efficiency of bYKL-40 capacitive immunosensors for different 
types of running buffer. (a) 10 mM sodium phosphate buffer, pH 7.0; (b) 10 mM 
HEPES buffer, pH 7.0; (c) 10 mM Tris-HCl buffer, pH 7.0. 
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3.1.3.2.3  Optimization of the pH of sodium phosphate-based running buffer 
  The influence of pH during the binding reaction was studied between 6.5 
and 8.0 for the fixed concentration of bYKL-40 (10 µg/L) in 10 mM sodium 
phosphate buffer of different pH (6.5, 7.0, 7.5, and 8.0). Figure 3.11 shows that the 
change of capacitance increased with a move in pH from 6.0 to 7.0 and then 
decreased as the pH increased further. This suggested that the response of capacitive 
bYKL-40 immunosensors in terms of a capacitance change due to antigen-antibody 
binding was maximal at pH 7.0. Accordingly, the sodium phosphate buffer was 
routinely adjusted to pH 7.0. 
 
 
Figure 3.11  The efficiency of capacitive bYKL-40 immunosensors for applications 
with 10 mM sodium phosphate running buffer at different pH. 
 
3.1.3.2.4  Optimization of the concentration of the running buffer 
  The ionic strength of a buffer increases with its salt concentration and the 
ionic strength were expected to influence the non-covalent antigen-antibody binding 
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and hence capacitive signal generation for the chosen type of immunosensor. In view 
of that 5, 10, 50 and 100 mM sodium phosphate running buffer solutions, pH 7.0 were 
tested in analytical runs for samples with the same level of bYKL-40 (10 µg/L) and 
the observed capacitance changes to bYKL-40/anti-bYKL-40 conjugation were 
compared. The outcome is shown in Figure 3.12, which provides the evidence that the 
change in sensor capacitance upon sample injection got bigger when moving from 5 
to 10 mM buffer salt concentration and then decreased with a further salt level raise.  
The highest signal, under otherwise identical conditions, was clearly observed for the 
10 mM sodium phosphate running buffer, pH 7.0 and this solution was thus chosen 
for quantitative analysis with the developed capacitive bYKL-40 immunosensing. 
 
  
Figure 3.12  The dependence of the efficiency of bYKL-40 quantification on different 
salt concentrations of the sodium phosphate buffer, pH 7.0. 
 
 
 
 
 
 
 
 
 
71 
 
 
3.1.3.2.5  Optimization of the flow rate 
  In a flow injection capacitive immunosensor system the flow rate of the 
running buffer passing through the electrochemical flow cell is a main factor affecting 
the yield of interaction between bYKL-40 and immobilized anti-bYKL-40. For a 
given sample injection, choice of a faster (slower) flow rate will correspond to a 
shorter (longer) time given for antigen capture and smaller (larger) immunosensor 
capacitance changes are the result of the variation. Thus, an adaptation of the 
parameter is providing a chance for signal optimization. The result of a capacitive 
bYKL-40 immunosensing with flow rates of 50 to 400 μL/min, worked with for 
bYKL-40 injections of 10 µg/L in 10 mM sodium phosphate buffer, pH 7.0, 
confirmed this expectation (Figure 3.13). The lowest flow rate of 50 μL/min offered 
for the bYKL-40 antigen the maximum time for finding of and binding to its 
conjugation partner anti-bYKL-40 on the gold electrode and indeed produced the 
highest change in specific capacitance. And the signal decreased when the flow rate 
was increased. However, as the difference between the signals observed at 50 and 100 
µL/min was not significantly different, preference as choice for routine application of 
the methodology was not given to the best 50 µL/min but 100 µL/min to compromise 
with the related to a short overall analysis time. 
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Figure 3.13 The dependence of the efficiency of bYKL-40 quantification with 
capacitive immunosensor readout for different running buffer flow rates. 
 
3.1.3.2.6  Optimization of the injected sample volume  
  Increasing (decreasing) the sample volumes that are injected into the 
analytical system will increase (decrease) the number of bYKL-40 analyte molecules 
brought to the immunosensor surface by the buffer stream. Obviously a sample 
volume variation will thus have an impact on the magnitude of the triggered 
capacitance change on the capturing immunosensor surface. The dependence of the 
sensor signal on sample volume was inspected in capacitive bYKL-40 immunosensor 
trials for injections of 100 to 400 μL of 10 µg/L of bYKL-40 standard solution. The 
results of the set of measurements are summarized in Figure 3.14. The change in 
capacitance signal actually increased with a change of the sample volume from 100 to 
200 µL. A further increase in sample volume did not lead to a continuation of the 
effect and the capacitance change instead stayed about constant. Accordingly, 200 µL 
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was chosen in all quantification trials as the sample volume as it relates to short 
analysis time and at the same time saves precious analyte. 
 
 
Figure 3.14  The dependence of the efficiency of bYKL-40 capacitive 
immunosensing on a variation of injected sample volume. 
 
 In summary capacitive bYKL-40 immunosensor work best for analyte 
identification and quantification when applied with a 10 mM sodium phosphate 
running buffer, pH 7.0, HCl solution, pH 2.5 as regeneration solution, 100 μL/min as 
flow rate and a 200 μL as a sample volume. These values became thus the standard 
settings for the following assessments of the analytical merits of the analytical scheme 
and all applications to model and real sample analyses, too. 
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3.1.3.3  The analytical performance of bYKL-40 immunosensors in flow 
operation 
3.1.3.3.1  Linearity range and limit of detection 
  Sequential injections of bYKL-40 standard solutions of concentrations from 
0.01 µg/L to 10
 
mg/L, inspected in triplicate for each concentration and with 
intermediate regeneration as described, were performed under optimal conditions to 
determine the linear dynamic range of the capacitive assay for bYKL-40 
quantification. Figure 3.15 shows the results of a typical calibration experiment, with 
the capacitance change plotted against the logarithm of the bYKL-40 concentration. A 
linear response was reproducibly obtained within the range of 0.1 µg/L to 1 mg/L. 
The linear regression equation was y = (12.3±0.3) log (x) + (107.4±1.4) and the 
correlation coefficient settled at 0.995. To investigate the limit of detection the 
running buffer (10 mM sodium phosphate buffer, pH 7.0) was injected into the 
immunosensor for twenty times under the optimum conditions. The standard 
deviation of 20 blank results was obtained at 0.30 and slope of the regression line 
(from 0.1 to 10 µg/L) was obtained at 12.11. So, the limit of detection was calculated 
from Eq. 2.4 that is limit of detection equal to 0.07±0.01 µg/L. A representative trace 
of the capacitance response of the sensor to 0.1 µg/L of bYKL-40 is shown in Figure 
3.16, to demonstrate the capability of the developed sensing scheme to indeed work at 
very low analyte levels. 
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Figure 3.15  Representation of a calibration curve as valid for routine capacitive 
bYKL-40 immunosensing. Screened was the sensor response to injections of bYKL-
40 standard solutions of concentrations from 0.01 µg/L to 10
 
mg/L, under pre-
identified optimal operational conditions. 
 
 
Figure 3.16  bYKL-40 immunosensor response to the injection of 0.1 µg/L of bYKL-
40 under pre-identified optimal operational conditions. 
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3.1.3.3.2  The stability of anti-bYKL-40 immobilized electrode 
  The reproducibility of the capacitive bYKL-40 immunosensors in flow 
operation in continuous use was investigated at pre-identified optimal operational 
conditions by repetitively detecting the change of the capacitance triggered by 
injections of a fixed concentration of bYKL-40 standard solution (10 µg/L) with also 
repeated sensor surface regenerations to remove bYKL-40 from the anti-bYKL-40 
immobilized on the electrode in between the injections. The performance of the 
modified electrode was evaluated for more than 3 days with about 15 sample 
injections per day. Figure 3.17 shows a plot of the percentage of restored activity of 
the anti-bYKL-40 immobilized electrode as function of number injection. As desired, 
the induced capacitance changes were highly reproducible and the percentage of 
restored immunosensor activity settled at an average level of 100.1±1.7% with a 
1.67% R.S.D. The stable behavior lasted for 40 cycles of sample injection and surface 
regeneration, then the percentage of restored activity dropped rapidly to much lower, 
actually unacceptable. To additional proof that the self-assembled thiol monolayer as 
carrier of the antibody did not get destroyed during long term analysis, the 
thiol/bYKL-40 modified gold electrodes were tested via cyclic voltammetry before 
and after a stability trial. No significantly difference in the appearance of the cyclic 
voltammograms were observed (Figure 3.18), indicating that the self-assembled 
thiourea monolayer remained to be intact upon repeated cyclic exposures to sample 
and regeneration solutions, at least for the number of injections studied in the long-
term tests. Therefore, the decrease in response of bYKL-40 immunosensors is most 
likely caused by a degradation of the antibody entities of the tool and their loss in 
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ability to well conjugate with the arriving corresponding antigen molecules rather 
than by a delamination and/or damage of the thiol monolayer. 
 
 
Figure 3.17  Assessment of the stability of the signal during repeated cycles of 
sample injection and immunosensor regeneration. 
 
 
Figure 3.18  The cyclic voltammograms in ferricyanide-containing electrolyte 
recorded before (black curve) and after (gray curve) the stability test. 
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3.1.3.3.3  The selectivity of capacitive bYKL-40 immunosensors 
  Inspected was also the effect of substances that might interfere with the 
response of bYKL-40 in the capacitive immunosensor system, when present in the 
sample solution. Two homolog proteins of YKL-40, namely YKL-39 and AMCase, 
were used as potent interferences to test the selectivity of the capacitive 
immunosensor system at a concentration range of 0.01 µg/L to 10 mg/L. Both 
candidates for interference produced, however, only very small capacitive responses 
of bYKL40 immunosensors, when compared with the one of the target analyte and 
designated antibody binding partner bYKL-40 (Figure 3.19). The responses of bYKL-
40 demonstrated pronounced concentration dependence but the responses of YKL-39 
and AMCase did not change with increase in their concentration with values about the 
same as triggered by running buffer injections.  Apparently the presence of the two 
species does not interfere with the detection of bYKL-40 and bYKL-40 capacitive 
immunosensor have indeed the particularly good selectivity to bYKL-40 that is 
predicted for a tailored antibody/antigen bio-conjugate couple.  
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Figure 3.19  Representative selectivity test for capacitive bYKL-40 immunosensors. 
The anti-bYKL-40 modified gold electrode was exposed either to the target analyte 
bYKL-40 and other members of the GH-18 (YKL-39 and AMCase) and thus potential 
candidates as interfering species. The capacitance change was evaluated under pre-
identical optimal operational conditions. (a), bYKL-40; (b), YKL-39; (c), AMCase 
and (d), injections of blank running buffer solution. 
 
3.1.3.4  Determination of YKL-40 in model and spiked serum samples 
  To demonstrate the use of the developed bYKL-40 capacitive immunosensor 
system for accurate analyte quantification, the system was applied to model and 
spiked serum samples of known concentration of YKL-40 and percentage of recovery 
calculations were used for judgment of the quality of the measurements, its was 
described in Eq. 2.5 in Chapter II, Section 2.3.2.7.1. All samples were analyzed with 
the flow-based capacitive bYKL-40 immunosensing scheme and also with the 
common ELISA, and the data from the two complementary assessments were 
compared. 
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  The immunosensors responses to particular sample injections were used to 
extract the actual YKL-40 concentration from the calibration curve that was obtained 
through work with YKL-40 standard solutions. Table 3.2 show the data for triplicate 
quantifications of spiked buffer solutions with added YKL-40 of a 0.5 to 50 µg/L 
level. It is well obvious that the set point levels were reproduced with a good 
percentage of recovery and the statistically analysis (One-Way ANOVA, p < 0.05), 
demonstrated that there was not significantly difference between data from the bYKL-
40 capacitive immunosensor and the common ELISA. 
 
Table 3.2  YKL-40 detection in model samples: a comparison of the results from 
bYKL-40 capacitive immunosensing with those from ELISA (n=3). 
Added  
(µg/L) 
Immunosensor ELISA 
Found  
(µg/L) 
Recovery 
(%) 
Found  
(µg/L) 
Recovery 
(%) 
0.50 0.50±0.01 99.15±2.63 N.d. N.d. 
2.50 2.50±0.04 100.27±2.66 2.57±0.05 102.12±2.21 
10.00 10.28±0.16 102.16±1.57 10.33±0.12 103.42±1.42 
50.00 50.82±2.62 101.75±2.70 50.48±0.15 102.11±3.11 
   N.d. = Not detection 
 
  The applicability of the capacitive biosensor for competitive YKL-40 
analysis became further evident by measuring the analyte in spiked serum samples, 
which were spiked with 25, 50, 80 and 100 µg/L of bYKL-40. Spiked serum samples 
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were 10 dilution times with running buffer to minimize a possible influence of 
components of the more demanding real sample matrix. Again, the capacitance 
response to particular sample injections was used to calculate the actual YKL-40 
sample concentration of from the pre-determined calibration curve for the 
immunosensor in use. ELISA measurements on all tested samples delivered data for 
comparison and validation. Table 3.3 shows a summary of the results that were 
obtained in course of the spiked serum tests. Evident is that bYKL-40 capacitive 
immunosensor can measure the concentration of YKL-40 in spiked serum samples 
accurately and in good agreement with the ELISA.  The percentage of recovery of the 
spiked YKL-40 levels in the four serum samples was between about 99.17±5.70% to 
106.68±2.39% and 99.44±0.43% to 101.92±3.22%, respectively. As for the model 
samples, the statistical analysis (One-Way ANOVA, p < 0.05) did not reveal any 
significantly difference between the data from bYKL-40 capacitive immunosensing 
and ELISA.  
  Altogether, above results demonstrated success with the establishment of 
flow injection-based capacitive bYKL-40 immunosensing and a good analytical 
performance for analyte quantification in both model and spiked blood serum 
samples. 
  Normally, the healthy person was expression levels of YKL-40 protein in 
serum around 40 µg/L (Johansen et al., 1995 and 2003, and Dupont et al., 2004). For 
the results of spiked serum samples in Table 3.3 shows the bYKL-40 capacitive 
immunosensor system and ELISA technique did not detect YKL-40 protein in non-
spiked serum of healthy person but both systems can detected only spiked 
concentration of bYKL-40 in serum of healthy person. These results indicated that our 
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anti-bYKL-40 polyclonal antibody, which produced from bacteria system, did not 
react with YKL-40 protein in human serum form. So, we change protocol for 
production of YKL-40 protein from bacteria expression system to mammalian 
expression system.  An alternative method for the expression of the YKL-40 protein is 
the use of a mammalian cell expression system. The main advantages of this optional 
expression system are that the signals for synthesis, processing and secretion of 
eukaryotic proteins are properly and efficiently recognized by the mammalian cells. In 
a continuation of the work already reported, access to the YKL-40 protein through 
mammalian expression system and use the obtained alternative protein for 
immunosensor preparation and application was thus explored. 
 
Table 3.3  YKL-40 detection in spiked serum samples: a comparison of the results 
from capacitive immunosensing with those from ELISA (n=3). 
Added  
(µg/L) 
Immunosensor ELISA 
Found  
(µg/L) 
Recovery 
(%) 
Found  
(µg/L) 
Recovery 
(%) 
0.00 N.d. - N.d. - 
25.00 25.09±1.20 100.38±4.79 25.51±0.81 101.92±3.22 
50.00 49.59 ±2.85 99.17±5.70 50.83±0.72 101.53±1.33 
80.00 85.35±1.91 106.68±2.39 79.51±0.31 99.44±0.43 
100.00 101.17±3.51 101.17±3.51 101.14±0.55 101.14±0.55 
   N.d. = Not detection 
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3.1.4   Expression and purification of YKL-40 in mammalian system (mYKL-40) 
  The recombinant plasmid of full-length YKL-40 DNA cloned into 
pCMV/hygro–His expression vector was obtained from Sino biological Inc., Beijing, 
China, which was ready to be expressed in 293T cell line. The recombinant protein 
was expressed with the 21-amino acid N-terminal signal sequence attached and His10-
tagged at C-terminal. 
  Recombinant YKL-40 was expressed in 293T cell line. After transfected 
recombinant plasmid to 293T cell line, culture medium that contains mYKL-40 
protein was collected. The mYKL-40 fraction was further purified by affinity 
chromatography using a Ni-NTA agaroes column run under gravity flow. The Figure 
3.20 shows 12% SDS-PAGE analysis of mYKL-40 purification by Ni-NTA agaroes, 
which migrated as a single band around 40 kDa (Lane 4 and 5), consistent with molar 
mass expected for mYKL-40 lacking the 21 amino acid signal peptide and has a 
predicted MW of 40,488 Da. The Figure 3.21 shows western blot analysis of the 
purified protein by commercial anti-YKL-40 (Quidel Corporation, San Diego, CA, 
USA); the results show the positive band of mYKL-40 protein in Elution fraction 1, 2 
and 3. These results show the successfully expressed and purified mYKL-40 protein. 
Subsequently the purified mYKL-40 protein was used as immunogenic for mYKL-40 
polyclonal antibody production by injected into subcutaneous of white New Zealand 
rabbit, 10 weeks age. 
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Figure 3.20  12% SDS-PAGE analysis of mYKL-40 purification by Ni-NTA agaroes.  
Lane M, protein marker; Lane 1, culture medium fraction; Lane 2, wash with 10 mM 
imidazole; Lane 3, wash with 20 mM imidazole; Lane 4-7, Elute with 250 mM 
imidazole. 
 
 
Figure 3.21  mYKL-40 proteins detected by immunoblotting with the anti-YKL-40. 
Lane M, protein marker; Lane 1, culture medium fraction; Lane 2, wash with 10 mM 
imidazole; Lane 3, wash with 20 mM imidazole; Lane 4-7, elute with 250 mM 
imidazole. 
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3.1.5   Production of mYKL-40 polyclonal antibody 
 Purified mYKL-40 protein was used for the production of mYKL-40 
polyclonal antibodies. The polyclonal anti-mYKL-40 antiserum was determined by 
western blot assay (Figure 3.22). The result shows the polyclonal anti-mYKL-40 
antiserum and commercial anti-mYKL-40 was reacted strongly with the mYKL-40 
target protein, shown in Figure 3.22B, Lane 2 and 3, respectively. In contrast, no 
signal was detected from the pre-immune serum (Figure 3.22B, Lane 1). The 
polyclonal anti-mYKL-40 antiserum titers were determined by western blot assay 
(Figure 3.23). The polyclonal anti-mYKL-40 antiserum reacted strongly with the 
mYKL-40 target protein at dilutions up to 1:40,000 and a faint signal were detectable 
even at 1:80,000 dilutions. In contrast, no signal was detected from the pre-immune 
serum, even at the highest concentration tested (1:2,500 dilutions). Evaluation of 
cross-reactivity against other members of GH-18 used a 1:40,000 dilutions of 
polyclonal anti-mYKL-40 antiserum. The western blots analysis (Figure 3.24B) 
revealed no interaction of the polyclonal anti-mYKL-40 antiserum with mYKL-40 
homologues such as YKL-39, AMCase and chitinases A, confirming that the 
polyclonal anti-mYKL-40 antiserum specific for the target protein, mYKL-40.  
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Figure 3.22 Reactivity of polyclonal anti-mYKL-40 antiserum. (A) 12% SDS-PAGE 
analysis of 2 μg of purified mYKL-40: Lane 1, coomassie-blue stained. (B) mYKL-40 
protein detected by western blot assay. Lane M, protein markers; Lane 1, pre-immune 
serum; Lane 2, polyclonal anti-mYKL-40 antiserum; Lane 3, commercial anti-YKL-
40. 
 
 
Figure 3.23  The polyclonal anti-mYKL-40 antiserum titers against 2 μg of purified 
mYKL-40. Lane M, protein markers; Lane 1–6, 2 μg of purified mYKL-40 protein 
detected with various dilutions (1:2,500, 1:5,000, 1:10,000, 1:20,000, 1:40,000 and 
1:80,000) of polyclonal anti-mYKL-40 antiserum (left-hand panel). The same 
dilutions of pre-immune serum were used as a negative control (right-hand panel). 
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Figure 3.24  Specificity of polyclonal anti-mYKL-40 antiserum. (A) Coomassie-blue 
stained 12% SDS-PAGE. (B) Western blot analysis with polyclonal anti-mYKL-40 
antiserum (1:40,000 dilution); pre-immune serum was used as a negative control (not 
shown). Lane 1, purified mYKL-40 protein (2 μg); Lane 2, YKL-39 (3 μg); Lane 3, 
AMCase (3 μg) and Lane 4, chitinases A (10 μg). 
 
  Polyclonal anti-mYKL-40 antiserum was purified by affinity chromatography 
on protein A agarose column run under gravity flow. The SDS-PAGE analysis 
(Figure 3.25) showed the purity of the anti-mYKL-40 polyclonal antibody, and 
confirmed that it is a protein A-specific IgG isotype. The immunoglobulin migrated 
above the 130 kDa marker under non-reducing conditions (Figure 3.25, Lane 2), 
while reduction of the sample produced two protein bands, of about 55 kDa and 22 
kDa (Figure 3.25, Lane 1), as expected for IgG isotype. IgG antibodies are large 
molecules of about 150 kDa, contains heavy chains of about 50 kDa and light chains 
of about 25 kDa. To check the reactivity of purified anti-mYKL-40 polyclonal 
antibody was determined by western blot assay. The western blot analysis of the 
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purified anti-mYKL-40 polyclonal antibody show the anti-mYKL-40 reacted strongly 
with mYKL-40 down to 0.250 mg/L, whereas the pre-immune serum showed no 
detected signal (Figure 3.26). 
 
 
Figure 3.25  Purification of anti-mYKL-40 polyclonal antibody by affinity protein A-
agarose column run under gravity flow. 12% SDS-PAGE analysis of purified anti-
mYKL-40 polyclonal antibody; Lane 1, under reducing conditions and Lane 2, non-
reducing conditions: coomassie-blue stained gel. 
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Figure 3.26  Purified anti-mYKL-40 polyclonal antibody titers against 2 μg of 
mYKL-40. Lane M, protein markers; Lane 1–6, serial dilutions of the purified 
antibody to 2, 1, 0.500, 0.250, 0.175 and 0.078 mg/L, respectively (left-hand panel). 
Unfractionated pre-immune serum was used as a negative control (right-hand panel). 
 
  To confirm the specificity of purified anti-mYKL-40 polyclonal antibody with 
related proteins was tested by using another commonly technique that is ELISA. 
Figure 3.27 shows the binding of anti-mYKL-40 polyclonal antibody to mYKL-40 
and homologus proteins. Figure 3.27 represent the binding curve of mYKL-40, 
showing concentration dependence of the anti-mYKL-40 polyclonal antibody towards 
the mYKL-40 protein and homologous proteins. The mYKL-40 (curve a) shown the 
hyperbolic plot of the interaction signal with increasing mYKL-40 protein 
concentration is characteristic of a specific antigen-antibody interaction. Whereas, 
other members of GH-18 (YKL-39 and AMCase) shown the no significant signal was 
obtained, YKL-39 (curve b) and AMCase (curve c). This well confirmed that the anti-
mYKL-40 polyclonal antibody was highly specific for mYKL-40 protein, target 
protein.  
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  The linearity range of mYKL-40 ELISA was obtained from 2.5 to 320 µg/L 
and the limit of detection is 2.5 µg/L. The linear regression equation is y = 
(0.005±0.001) x + (0.019±0.006) at the correlation coefficient at 0.997. 
  These results confirmed that the purified anti-mYKL-40 was highly specific 
for mYKL-40 protein and thus suitable for use in mYKL-40 capacitive immunosensor 
based flow injection system. 
 
 
Figure 3.27  mYKL-40 Enzyme-linked immunosorbent assay. Binding of anti-
mYKL-40 IgG (50 µL, 10 µg/L) to different amounts of surface-attached mYKL-40 
related proteins: mYKL-40 (curve a); YKL-39 (curve b); and AMCase (curve c). Inset 
show the signal response at low concentration of mYKL-40. 
 
3.1.6   Capacitive mYKL-40 immunosensor 
3.1.6.1  Preparation of the immunosensors 
  As above described in detail (section 3.1.3.1), the insulating properties of 
modified gold electrode have been inspected after individual preparation steps via 
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cyclic voltammograms in ferricyanide-containing electrolytes. The gradual 
disappearance of the Fe (III)/Fe (II) redox peaks in the voltammograms again was 
taken as evidence of thiol monolayer assembly, antibody immobilization, and 
complete insulation reach via residual exposed electrode surface coverage with 1-
dodecanethiol (Figure 3.28). 
   
 
Figure 3.28  Cyclic voltammograms of a gold electrode at various surface conditions. 
(a) clean (b) coated with a self-assembled thiourea monolayer, (c) after glutaraldehyde 
exposure of the thiourea film, (d) after anti-mYKL-40 bonding to the glutaraldehyde-
treated thiourea film and (e) after final treatment with 1-dodecanethiol. 
 
3.1.6.2  Optimization of operational conditions 
  Again, the experimental parameters affecting the performance of the 
capacitive immunosensor (now just with an YKL-40 antibody from the mammalian 
cell expression system) in the already introduced flow injection system was 
investigated and optimized to yield optimal analytical performance. Evaluations 
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considered the regeneration solution, the running buffer, injected sample volume and 
flow rate. All measurements were carried out as above described in detail for the 
bYKL-40 protein derived from the bacterial cell expression system and were again 
performed in triplicate. The data of the optimization trials with mYKL-40 
immunosensors incorporating anti-mYKL-40 polyclonal antibody produced via 
mYKL-40 derived from the mammalian cell expression system are summarized in 
Figures 3.29 - 3.35. Optimal conditions for the operation of the alternative type of 
capacitive mYKL-40 immunosensor were: regeneration solution, HCl solution, pH 
2.5; running buffer, 25 mM sodium phosphate buffer, pH 7.0; sample volume, 250 μL 
and flow rate, 100 μL/min. 
 
 
Figure 3.29 Efficiency of different types of regeneration solutions. Percentage of 
restored activity is an expression that scales the amount of immobilized anti-mYKL-
40 antibody that got released from mYKL-40 antigen that had been captured in course 
of a measurement cycle; the higher the percentage of restored activity, the more 
antibody was freed and successfully primed for capturing antigen again in the next 
analytical sample injection run. 
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Figure 3.30  The influence of the pH of the HCl regeneration solution on the 
efficiency of removal mYKL-40 from anti-mYKL-40 on a thiol-coated gold 
electrode. 
 
 
Figure 3.31  The efficiency of mYKL-40 capacitive immunosensors for different 
types of running buffer. (a) 10 mM sodium phosphate buffer pH 7.0; (b) 10 mM 
HEPES buffer pH 7.0; (c) 10 mM Tris-HCl buffer pH 7.0. 
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Figure 3.32  The efficiency of mYKL-40 capacitive immunosensors for applications 
with 10 mM sodium phosphate running buffer at different pH. 
 
 
Figure 3.33  The dependence of the efficiency of mYKL-40 quantification on 
different salt concentrations of the sodium phosphate buffer, pH 7.0. 
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Figure 3.34  The dependence of the efficiency of mYKL-40 capacitive 
immunosensing on a variation of injected sample volume. 
 
 
Figure 3.35  The dependence of the efficiency of mYKL-40 quantification with 
capacitive immunosensor readout for different running buffer flow rates. 
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3.1.6.3  The analytical performance of mYKL-40 immunosensors in flow 
operation 
3.1.6.3.1  Linearity range and limit of detection 
  Tested via triplicate injections of standard solutions of mYKL-40 in the 
range 1 ng/L to 100 mg/L the immunosensor system with the antibody/antigen 
obtained from the mammalian expression system offered under the pre-identical 
optimal operational conditions a linear range between 0.1 µg/L to 1 mg/L (Figure 
3.36). The corresponding linear equation of the regression line y = (19.9±0.5) log (x) 
+ (156.3±0.6) and the plot had a correlation coefficient of 0.992. At concentration 
above 1 mg/L the capacitance signal became constant because of the saturation of all 
immobilized antibody entities with mYKL-40 antigen. To investigate the limit of 
detection the running buffer (25 mM sodium phosphate buffer, pH 7.0) was injected 
into the immunosensor for twenty times under the optimum conditions. The standard 
deviation of 20 blank results was obtained at 0.55 and slope of the regression line 
(from 0.1 to 10 µg/L) was obtained at 19.90. So, the limit of detection was calculated 
from Eq.2.4 that is the limit of detection was about 0.08±0.02 µg/L. 
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Figure 3.36  Representation of a calibration curve as valid for routine capacitive 
mYKL-40 immunosensing. Screened was the sensor response to injections of mYKL-
40 standard solutions of concentrations from 1 ng/L to 100
 
mg/L under pre-identified 
optimal operational conditions. 
 
3.1.6.3.2  The stability of capacitive mYKL-40 immunosensors 
  In similar manner as before done for the immunosensors with a bYKL-40 
antibody/antigen couple originating from bacterial cell expression the new option 
gained from the mammalian cell expression was also subjected to a stability trial. 
Figure 3.37 shows a display of a plot of the percentage of restored activity of for the 
anti-mYKL-40 electrode as a function of the number of regeneration cycles at the 
time of measurement. Evident is that for more than 3 days, which is the equivalent of 
50 cycles of analyte injection and immunosensor detection and regeneration, the 
percentage of restored activity of was at a very good level of 98.8±0.9% (0.85% RSD) 
of the original capacitance change. And again the acquisition of equality of cyclic 
voltammograms for sensors before and after the long-term stability test demonstrated 
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self-assembled monolayer intactness and pointed toward structural and/or chemical 
antibody modification and related loss of antigen binding ability (Figure 3.38). 
 
 
Figure 3.37  Assessment of the stability of the signal during repeated cycles of 
sample injection and immunosensor regeneration. 
 
 
Figure 3.38  The cyclic voltammograms in ferricyanide-containing electrolyte 
recorded before (black curve) and after (gray curve) the stability test. 
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3.1.6.3.3  The selectivity of anti-mYKL-40 immunosensors 
  Following the strategy handled for the selectivity tests on immunosensors 
with antibody from the bacterial cell expression, the mYKL-40 antibody based on the 
mammalian cell expression was tested in the flow-based capacitive immunosensor 
system with samples that had on top of the target analyte also its homologus proteins 
(YKL-39 and AMCase). Tests were of course done as a sort of calibration run with 
the capacitive immunosensor system used for the concentration range from 1 ng/L to 
100 mg/L), under the pre-identified optimal operational conditions. The two 
homologus protein samples tested in the mYKL-40 capacitive immunosensor system 
produced capacitance changes not larger than injections of running buffer solution. 
Injections of samples with the target analyte, mYKL-40, however, changed the 
capacitance nicely in concentration-dependent manner (Figure 3.39). Conclusion was 
thus that YKL-39 and AMCase presence does not cause interference problems, even 
though the proteins are structurally and chemically very closely related to the target 
antigen. The identified specificity made tests in model and real samples practical. 
They are described in the following sub-chapter. 
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Figure 3.39  Representative selectivity test for capacitive mYKL-40 immunosensors. 
The anti-mYKL-40 modified gold electrode was exposed either to the target analyte 
mYKL-40, and other members of the GH-18 (YKL-39 and AMCase) and thus 
potential candidates as interfering species. The capacitance change was evaluated 
under the pre-identified optimal operational conditions. (a), mYKL-40; (b), YKL-39; 
and (c), AMCase. 
 
3.1.6.4  Determination of YKL-40 in model and clinical samples 
  Triplicate quantification was approached with the capacitive immunosensors 
for model samples that were spiked with three different YKL-40 concentrations in the 
range of 30 to 150 µg/L. In parallel analytical trials the concentrations of the three 
samples were also determined by an in-house and a commercial ELISAs (BlueGene 
Biotech CO., LTD). Obtained data proved a good agreement of the YKL-40 levels 
reported by the three methods. The percentage of recovery for the quantifications by 
the capacitive immunosensor and the in-house and the commercial ELISAs were 
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100.1±0.6 to 102.2±1.9%, 98.9±0.6 to 99.9±0.2% and 100.5±2.1 to 100.6±0.6%, 
respectively (Table 3.4). Data inspection by statistical analysis pointed out that there 
were no systematic differences between the results from the three methodologies 
(One-Way ANOVA, p < 0.05). Sensors were then further applied for YKL-40 
assessments in clinical samples of healthy people, suitable cell lysate samples and 
samples from people with cancer. 
 
Table 3.4  YKL-40 detection in model samples: a comparison of the results from 
mYKL-40 capacitive immunosensing with those from ELISA (n=3). 
Added 
(µg/L) 
Immunosensor In-house ELISA  Commercial ELISA  
Found 
(µg/L) 
Recovery 
(%) 
Found 
 (µg/L) 
Recovery 
(%) 
Found 
 (µg/L) 
Recovery 
(%) 
0 N.d. - N.d. - N.d. - 
30 30.7±0.7 102.2±1.9 29.7±0.2 98.9±0.6 30.1±0.8 100.5±2.1 
40 40.8±1.0 101.9±2.1 39.7±0.6 99.2±1.2 40.3±0.3 100.6±0.6 
150 150.2±1.2 100.1±0.6 149.8±0.4 99.9±0.2 150.1±0.8 100.8±0.9 
              N.d. = Not detection 
 
 The clinical application of capacitive mYKL-40 immunosensors was first 
explored for four hospital serum samples from healthy persons, labeled here simply as 
H1-H4. Prior to analysis, the serum samples were diluted 10 times to reduce the 
possible impact of other proteins in the complex serum matrix on capacitive signal 
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generation at the immunosensor and in the ELISA, both in-house and commercial. 
The outcome of the three trials is shown in Table 3.5, which provides the evidence 
that the concentrations determined by the capacitive immunosensor, in-house ELISA 
and commercial ELISA are in good agreement with each other and they were in 
accordance with reported values in the literature. The actual level of YKL-40 in the 
four healthy person range of 60 to 75 µg/L. The quality of analysis was confirmed 
through measurements of by spiked serum samples that had been up scaled with 50 
µg/L of YKL-40. As expected the measured level of YKL-40 in the spiked healthy 
person samples shifted to higher levels and with exact values from 100 to 125 µg/L 
(found concentration + spiked concentration) the percentage of recovery were very 
close to the ideal 100%. In summary all three analysis techniques applied in the trials 
could actually reveal correctly the native YKL-40 in healthy human serum; no 
significantly difference in the values were observed (One-Way ANOVA, p < 0.05). 
Apparently, the developed mYKL-40 immunosensor system was suitable for the 
detection of target YKL-40 in healthy human serum.   
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Table 3.5  YKL-40 detection in serum samples from a healthy person: a comparison 
of the results from mYKL-40 capacitive immunosensing with those from 
ELISA (n=3). 
Healthy 
person 
Immunosensor 
(µg/L) 
In-house ELISA  
(µg/L) 
Commercial ELISA  
(µg/L) 
   H1 75.4±1.4 74.5±1.9 75.1±0.8 
   H2 60.4±1.1 59.9±1.9 60.2±0.1 
   H3 66.3±1.4 66.5±3.8 66.7±0.2 
   H4 51.7±2.5 51.9±5.0 51.7±0.4 
   H1 + 50 µg/L 125.0±2.3 126.5±3.8 124.9±0.6 
   H2 + 50 µg/L 109.4±1.3 109.2±3.3 111.3±0.7 
   H3 + 50 µg/L 116.8±0.4 115.9±1.9 117.0±0.5 
   H4 + 50 µg/L 100.8±0.9 101.2±3.3 101.0±0.2 
 
  Known from the literature review was that YKL-40 levels were higher in 
serum samples of patients with, for instance, breast cancer, colorectal cancer, ovarian 
cancer, small cell lung cancer, prostate cancer, and glioblastoma. Inspected here for 
their YKL-40 content were the blood serum samples from 5 breast (named B1-B5) 
and 4 glioblastoma (named G1-G4) cancer patients, again via mYKL-40 capacitive 
immunosensing and in-house and commercial ELISAs. The nine serum samples were 
kind provision of the Maharat Nakhon Ratchasima Hospital in Nakhon Ratchasima, 
Thailand and they were as a routine diluted at 10 times with running buffer to 
minimize matrix effects. Table 3.6 is a presentation of the outcome of the trial on the 
cancer patient’s blood serum. Noticed can be that the concentrations that determined 
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by the capacitive immunosensor, in-house ELISA and commercial ELISA are close to 
each other. In fact, the YKL-40 levels of the five breast cancer patients ranged from 
about 40 (low) to 400 (high) µg/L while the four glioblastoma patients had blood 
serum with 50 (low) to 650 (high) µg/L of YKL-40. Recovery tests were carried out 
with spiked samples (B3 + 50 µg/L of YKL-40 and G1+ 50 µg/L of YKL-40) and the 
percentage of recovery for both attempts were close to the ideal 100%.  Evidence was 
thus gained that not only the native YKL-40 level of healthy human blood serum can 
be determined accurately but also the elevated equivalents due to cancer.  No 
significantly difference became evident between the suggested electrochemical 
capacitive immunosensor screen and an ELISA with optical readout (One-Way 
ANOVA, p < 0.05). 
 
3.1.6.5  Determination of YKL-40 in cell lysates 
  Michelsen et al. (2010) reported the YKL-40 expression by THP-1 (human 
leukemia cell line) cells while 293T cells had not been linked with YKL-40 
generation. THP-1 and 293T cell lysates were thus nice samples for comparative 
performance tests with the mYKL-40 capacitive immunosensor and the in-house and 
commercial ELISAs. The results of the application of the three assays on the two cell 
lysates are shown in Table 3.6. In good agreement with the expectation all schemes 
reported similar YKL-40 concentrations in the THP-1 cell lysate, and did not detect 
noticeable levels of the analyte in 293T cell lysates. This was further supported of the 
impression that capacitive mYKL-40 immunosensing is a trustful novel analytical 
approach for the detection and quantification of this biomarker molecule. Since 293T 
cell lysates was confirmed to be YKL-40 free this liquid offered the chance of control 
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quantifications in a more complex sample matrix with a defined adjustment of the 
protein analyte.  Accordingly, 293T cell lysates were spiked with 50 µg/L of YKL-40 
and jointly all the capacitive electrochemical and the optical ELISAs revealed the 
adjusted level with good percentage of recovery (see Table 3.7). 
 
Table 3.6  YKL-40 detection in serum samples from cancer patients: a comparison of 
the results from mYKL-40 capacitive immunosensing with those from 
ELISA (n=3). 
Clinical Samples 
Immunosensor 
(µg/L) 
In-house ELISA 
(µg/L) 
Commercial ELISA 
(µg/L) 
   B1 42.5±0.8 43.3±1.9 42.2±0.5 
   B2 87.1±0.1 87.3±1.9 86.3±1.1 
   B3 399.8±2.4 399.3±2.3 400.5±2.6 
   B4 212.9±1.4 212.7±3.8 214.8±1.4 
   B5 47.3±1.3 47.3±1.9 47.6±1.1 
   B3 + 50 µg/L 449.4±4.2 450.0±3.3 451.8±3.9 
   G1 654.6±1.5 654.0±3.3 653.0±0.7 
   G2 143.7±2.6 143.3±1.9 144.0±1.0 
   G3 47.7±0.7 47.3±1.9 46.9±0.3 
   G4 96.3±1.6 95.3±1.9 95.9±0.5 
   G1 + 50 µg/L 705.6±4.7 700.7±1.9 709.2±2.9 
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Table 3.7  YKL-40 detection in cell lysates from cancer patient: a comparison of the 
results from mYKL-40 capacitive immunosensing with those from ELISA 
(n=3). 
Samples 
Immunosensor 
(µg/L) 
In-house ELISA 
(µg/L) 
Commercial ELISA 
(µg/L) 
THP-1 87.3±1.5 86.0±3.3 86.4±2.2 
293T N.d. N.d. N.d. 
293T + 50 µg/L 49.7±0.2 50.5±1.9 49.2±0.3 
  N.d. = Not detection 
 
3.2   Capacitive immunosensor for detection of YKL-39 
3.2.1   Preparation of YKL-39 immunosensors 
  As above described in detail for the inspections in course of YKL-40 
preparation (Chapter III, Section 3.1.3.1), the insulating properties of modified gold 
electrode have been inspected after individual preparation steps of YKL-39 
immunosensor fabrication via cyclic voltammetry in ferricyanide-containing 
electrolytes. The gradual disappearance of the Fe (III)/Fe (II) redox peaks in the 
voltammograms again was taken as evidence of thiol monolayer assembly, antibody 
immobilization, and complete insulation reach via residual exposed electrode surface 
coverage with 1-dodecanethiol (Figure 3.40). 
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Figure 3.40  Cyclic voltammograms of a gold electrode at various surface conditions. 
(a) clean (b) coated with a self-assembled thiourea monolayer, (c) after glutaraldehyde 
exposure of the thiourea film, (d) after anti-YKL-39 bonding to the glutaraldehyde-
treated thiourea film and (e) after final treatment with 1-dodecanethiol. 
 
3.2.2   Optimization of conditions for YKL-39 operation in the electrochemical 
flow cell 
  As for YKL-40 immunosensors, the experimental parameters affecting the 
performance of the capacitive immunosensor (now just with an YKL-39 antibody on 
the sensor surface) in the already introduced flow injection system was investigated 
and optimized to yield optimal analytical performance. Evaluations considered the 
regeneration solution, the running buffer, injected sample volume and flow rate. All 
measurements were carried out as above described in detail for the YKL-40 protein 
and were again performed in triplicate.  The data of the optimization trials with YKL-
39 immunosensors incorporating YKL-39 antibody are summarized in Figures 3.41 - 
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3.47. Optimal conditions for the operation of capacitive YKL-39 immunosensors 
were: regeneration solution, HCl solution, pH 2.5; running buffer, 25 mM sodium 
phosphate buffer, pH 7.0; sample volume, 200 μL and flow rate, 100 μL/min. 
 
 
Figure 3.41  Efficiency of different types of regeneration solutions. Percentage of 
restored activity is an expression that scales the amount of immobilized YKL-39 
antibody that got released from YKL-39 antigen that had been captured in course of a 
measurement cycle; the higher the percentage of residual activity, the more antibody 
was free and successfully primed for capturing antigen again in the next analytical 
sample injection run. 
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Figure 3.42  The influence of the pH of the HCl regeneration solution on the 
efficiency of removal YKL-39 from anti-YKL-39 on a thiol-coated gold electrode. 
 
 
Figure 3.43  The efficiency of YKL-39 capacitive immunosensors for different types 
of running buffer. (a) 10 mM sodium phosphate buffer, pH 7.0; (b) 10 mM HEPES 
buffer, pH 7.0; (c) 10 mM Tris-HCl buffer, pH 7.0. 
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Figure 3.44  The efficiency of YKL-39 capacitive YKL-39 immunosensors for 
applications with 10 mM sodium phosphate running buffer at different pH. 
 
 
Figure 3.45  The dependence of the efficiency of YKL-39 quantification on different 
salt concentrations of the sodium phosphate buffer, pH 7.0.  
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Figure 3.46  The dependence of the efficiency of YKL-39 capacitive immunosensing 
on a variation of injected sample volume. 
 
 
Figure 3.47  The dependence of the efficiency of YKL-39 quantification with 
capacitive immunosensor readout for different running buffer flow rates. 
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3.2.3   YKL-39 immunosensor performance in the electrochemical flow cell 
  After the operational conditions for capacitive YKL-39 immunosensors were 
optimized, they were exposed at the identified best settings to analytical performance 
tests in the flow-based electrochemical workstation. 
 
3.2.3.1  Linearity range and limit of detection 
  To identify the practical linear range YKL-39 standard solutions of 1 ng/L to 
100 mg/L were quantified by the capacitive immunosensor system. An example of the 
obtained calibration curves is shown in Figure 3.48. The triplicate measurements of 
all analyte concentrations revealed a linearity in between 0.1 µg/L and 1 mg/L; the 
linear regression equation y = (16.1±0.4) log (x) + (137.2±2.4) had a very good 
correlation coefficient of 0.99. As already observed for the anti-YKL-40/YKL-40 
immunosensors, the magnitude of the capacitance change of YKL-39 in response to 
antigen injection reached plateau level for concentrations above 1 mg/L, because of 
the saturation of antibody entities on the sensor surface. To investigate the limit of 
detection the running buffer (25 mM sodium phosphate buffer, pH 7.0) was injected 
into the immunosensor for twenty times under the optimum conditions. The standard 
deviation of 20 blank results was obtained at 0.41 and slope of the regression line 
(from 0.1 to 10 µg/L) was obtained at 16.09. So, the limit of detection was calculated 
from Eq.2.4 that is the limit of detection was about 0.07±0.02 µg/L. 
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Figure 3.48  Representation of a calibration curve as valid for routine capacitive 
YKL-39 immunosensing. Screened was the sensor response to injections of YKL-39 
standard solutions of concentrations from 1 ng/L to 100
 
mg/L under pre-identified 
optimal operational conditions. 
 
3.2.3.2  Stability of capacitive YKL-39 immunosensors 
  In similar manner as before done for YKL-40 capacitive immunosensors, 
YKL-39 was also subjected to a stability trial. Figure 3.49 shows a display of a plot of 
the percentage of restored activity of the anti-YKL-39 immobilized electrode as a 
function of the number of regeneration cycles at the time of measurement. Evident is 
that for more than 3 days (an equivalent of 49 cycles of analyte injection and 
immunosensor detection and regeneration) the percentage of restored activity was at a 
very good level of 99.5±1.5% (1.5% RSD) of the original capacitance change. The 
acquisition of almost identical cyclic voltammograms for sensors before and after the 
long-term stability test was an evidence of self-assembled thiolurea monolayer 
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intactness and indicated structural and/or biological function of antibody degradation 
as reason for a loss of antigen binding ability (Figure 3.50). 
 
 
Figure 3.49  Assessment of the stability of the signal during repeated cycles of 
sample injection and immunosensor regeneration. 
 
 
Figure 3.50  The cyclic voltammograms in ferricyanide-containing electrolyte 
recorded before (black curve) and after (gray curve) the stability test.  
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3.2.3.3  The selectivity of YKL-39 immunosensors 
  Following the strategy handled for the selectivity tests on YKL-40 capacitive 
immunosensors, the YKL-39 capacitive immunosensors were tested in the flow-based 
capacitive immunosensor system with samples that had on top of the target analyte 
also the homolog proteins YKL-40 and AMCase present. Tests were actually 
analytical calibration runs with the capacitive immunosensor system tried for the 
concentration range from 1 ng/L to 100 mg/L), under the optimal operation 
conditions. While YKL-40 and AMCase in the tests did not produce capacitance 
changes larger than seen for injections of bare buffer solution, injections of the target 
analyte YKL-39 changed the capacitance as expected in noticeable and concentration-
dependent manner (Figure 3.51). Conclusion was thus at this stage that YKL-40 and 
AMCase presence do not cause interference problems, even though the two proteins 
are structurally and chemically very closely related to the target antigen YKL-39. The 
identified specificity made tests in model and real samples practical. They are 
described in the following sub-chapter. 
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Figure 3.51  Representative selectivity test for capacitive YKL-39 immunosensors. 
The anti-YKL-39 modified gold electrode was exposed either to its the target analyte 
YKL-39 and the proteins GH-18 members ( YKL-40 and AMCase) and thus potential 
candidates as interfering species. The capacitance change, was evaluated under 
optimal assay conditions. (a), YKL-39; (b), YKL-40; and (c), AMCase; (d), injections 
of blank running buffer solution. 
 
3.2.4   Enzyme-linked immunosorbent assay for detection of YKL-39 
  The common method used for the detection of YKL-39 is ELISA technique. 
YKL-39 standard solutions of concentration range from 1 to 500 µg/L were used for 
ELISA to investigate the linearity range and limit of detection. The linearity of the 
response was determined by plotting the calibration curve between A450 absorbance 
and YKL-39 concentration. Linearity was obtained from 2.5 to 125 µg/L with the 
linear regression equation; y = (0.006±0.001) x + (0.04±0.01), regression coefficient 
at 0.992 (Figure 3.52). The detection limit of the YKL-39 ELISA was 2.5
 
µg/L.   
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Figure 3.52  YKL-39 ELISA technique. Binding of purified anti-YKL-39 IgG (50 
µL, 15 µg/L) to different concentrations of surface-attached YKL-39 related proteins: 
YKL-39 (a); YKL-39 (b); AMCase (c) and chitinases A (d). Inset shows the signal 
response at low concentration of YKL-39 and related protein. 
 
3.4.5   Determination of YKL-39 in model and clinical samples 
  To get a first idea about the ability of YKL-39 immunosensor to quantify 
YKL-39 protein in samples with reasonable accuracy, a series of model samples were 
analyzed by using YKL-39 capacitive immunosensors and the results were compared 
with the YKL-39 ELISA. The model samples spanned the concentration range of 0.5 
to 150 µg/L and they were tested by the immunosensor system at the pre-identified 
optimum operational settings. The capacitance response to individual sample 
injections was used to compute corresponding sample concentration of YKL-39 from 
the calibration curve. The results from the trial on of model samples are shown in 
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Table 3.8. Capacitive YKL-39 immunosensors detected their target YKL-39 with a 
good percentage of recovery close to the ideal 100% and in agreement with the data 
from the comparative ELISA measurements. While capacitive immunosensing was 
able to handle the lowest (0.5 µg/L) and highest (150 µg/L) model sample YKL-39 
levels, the ELISA failed for this two situations because the concentrations were out of 
the more limited linear range of the optical screen. This failure nicely demonstrated 
that the advantage of capacitive immunosensing of YKL-39 in terms of the gain of a 
broader linear range. For all other samples the application of statistically analysis 
(One-Way ANOVA, p < 0.05) revealed that there were no systematic differences 
between the results obtained from capacitive YKL-39 immunosensing and ELISA. 
Based on the outcome of the model samples analysis, the methodology of YKL-39 
capacitive immunosensing was applied with confidence for the quantitative analysis 
of the YKL-39 content in real/clinical samples (synovial fluid of osteoarthritis 
patients and cell lysates). 
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Table 3.8  YKL-39 detection in model samples: a comparison of the results from 
YKL-39 capacitive immunosensing with those from ELISA (n=3). 
Added 
(µg/L) 
Immunosensor ELISA 
Found  
(µg/L) 
Recovery 
(%) 
Found  
(µg/L) 
Recovery 
(%) 
0.50 0.52±0.01 103.93±1.40 N.d. N.d. 
2.50 2.52±0.03 100.75±1.18 2.49±0.08 99.56±3.08 
5.00 5.02±0.19 100.47±3.83 5.24±0.13 104.89±2.67 
50.00 51.23±0.32 102.47±0.65 48.80±1.39 99.60±2.68 
150.00 149.99±2.48 100.00 ±1.65 105.24±0.80 70.16±0.53 
 N.d. = Not detection 
 
 Four synovial fluids from osteoarthritis patients were obtained from Maharat 
Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand and they were analyzed 
with capacitive YKL-39 immunosensing and the ELISA. Both analytical techniques 
were also used for YKL-39 quantifications in the cell lysates of Jurkat, U937, and 
293T cells. Prior to quantification trials, YKL-39 presence was screened for by using 
an immunoblot assay. Figure 3.53B shows the immunoblot for detection of YKL-39 
in the synovial fluid samples from osteoarthritis patients and in the chosen cell 
lysates. Obvious are strongly react with YKL-39 protein band for the synovial fluids 
and also for Jurkat and U937 cell lysates while the lysate of 293T cells did not 
produce a visible specific band for the YKL-39 protein. 
 Prior to quantitative analysis with the electrochemical or ELISA scheme, the 
synovial fluids and cell lysates were 10 times diluted with 25 mM sodium phosphate 
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buffer, pH 7.0 to minimize an adverse influence of non-targeted matrix components 
on signal generation. 200 µL of the diluted samples were then injected into the 
immunosensor system under optimum conditions. Figure 3.54 displays the 
capacitance response of the anti-YKL-39 modified electrode upon injections of the 
various samples. The base-line capacitance of the sensor surface exposed to flowing 
running buffer was first recorded and stored (left-hand side, Figure 3.54). After 
samples injection, appearance of conjugate formation between YKL-39 and anti-
YKL-39 should cause the sensor capacitance to decrease. All four synovial fluids, and 
the Jurkat and U937 cell lysates indeed induced a considerable capacitance decrease, 
whereas 293T cell lysates injection virtually left the capacitance signal unchanged 
(the capacitance signal same with blank control). These observations are in good 
agreement with the findings made via western blot analysis (Figure 3.53B). The YKL-
39 levels from the determination of the various samples are shown in Table 3.9. Both 
used methods measured the levels of YKL-39 in synovial fluid of osteoarthritis 
patients and Jurkat and U937 cell lysates similarly. The absence of YKL-39 in 293T 
cell lysates was also signaled by both analytical schemes. A comparison of the data 
from capacitive immunosensing and ELISA via One-Way ANOVA analysis (p < 
0.05) suggested that they determined the level of YKL-39 with good statistical 
correlation. 
 In a final trial YKL-39 at levels of 20 and 30 µg/L where added to otherwise 
YKL-39 free 293T cell lysates and the spiked concentrations were determined or 
percentage of recovery assessments by the YKL-39 capacitive immunosensor and the 
ELISA. The results of these measurements are shown in Table 3.10. The valid 
percentage of recovery was close to the ideal 100% for both techniques, which was 
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further evidence that capacitive YKL-39 immunosensing functions well as alternative 
option to the common ELISA.  
 
  
Figure 3.53  Detection of YKL-39 in real/clinical samples by immunoblot assay. 
Lane M, protein marker; Lane 1 – 4, synovial fluid from four osteoarthritis patient; 
Lane 5, Jurkat cell lysates; Lane 6, U937 cell lysates; Lane 7, 293T cell lysates; Lane 
8, YKL-39 (2 μg) were resolved on a 12% SDS-PAGE. (A) Coomassie-blue stained 
gel. (B) Immunoblot detected with anti-YKL-39 polyclonal antibody (1:10,000 
dilution).  
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Figure 3.54  Capacitance response of anti-YKL-39-modified electrode. The samples 
were injection (black arrow) into the flow buffer produce a decreasing of capacitance. 
, Blank (running buffer); , Jurkat cell lysates; , U937 cell lysates,  , 293T cell 
lysates;  osteoarthritis patient  1 - 4. 
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Table 3.9  YKL-39 detection in clinical samples: a comparison of the results from 
YKL-39 capacitive immunosensing with those from ELISA (n=3). 
Samples 
Immunosensor  
(µg/L) 
ELISA  
(µg/L) 
Synovial fluid # 1 59.4±2.4 58.3±3.4 
Synovial fluid # 2 106.3±0.8 107.0±2.5 
Synovial fluid # 3 68.1±1.3 67.7±1.2 
Synovial fluid # 4 89.0±2.7 88.8±1.6 
Jurkat 26.4±0.4 25.2±3.1 
U937 10.6±0.3 9.8±0.8 
293T N.d. N.d. 
   N.d. = Not detection 
 
Table 3.10  YKL-39 detection in spiked 293T cell lysate: a comparison of the results 
from YKL-39 capacitive immunosensing with those from ELISA (n=3). 
Added 
(µg/L) 
Immunosensor ELISA 
Found  
(µg/L) 
Recovery 
(%) 
Found  
(µg/L) 
Recovery 
(%) 
0 N.d. - N.d. - 
20 20.2±0.4 100.8±2.2 20.5±0.5 102.4±1.8 
30 29.7±0.2 99.1±0.7 30.4±0.5 101.2±1.2 
  N.d. = Not detection 
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CHAPTER IV 
DISCUSSION 
 
4.1  Capacitive immunosensor for detection of YKL-40 
Firstly, YKL-40 protein was expressed in bacterial and mammalian expression 
systems. The recombinant YKL-40 was expressed in the E. coli M15 (pREP) strain 
and 293T cell line. In bacterial expression system, the bulk of induce YKL-40 protein 
was insoluble, suggesting that it was present in inclusion bodies. The insoluble YKL-
40 protein was solubilized in 8 M urea and the YKL-40 fraction was further to 
purified by using Ni-NTA agarose column. Whereas in mammalian expression 
system, the YKL-40 protein was solubilized in culture medium and the YKL-40 
protein was further purified by affinity chromatography using a Ni-NTA agaroes 
column. The molecular weight of the purified YKL-40 estimated from SDS-PAGE 
was consistent with the molar weight expected for human YKL-40 lacking the 20 
amino acid signal peptide, with the predicted MW of 40,488 Da. 
The both of purified YKL-40 protein were used for the production of anti-
YKL-40 polyclonal antibody. The both of polyclonal antiserum strongly reacted with 
YKL-40 and evaluation of cross-reactivity against other member of GH-18 revealed 
no interaction of the both of polyclonal antiserum with YKL-40 homologues such as 
YKL-39, AMCase and bacteria chitinases. The results confirmed that the raised both 
of polyclonal antiserum was specific for the YKL-40 protein. The both of anti-YKL- 
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40 antiserum were fractionated by affinity chromatography on protein A agarose. 
SDS-PAGE analysis showed that the purified anti-YKL-40 migrated behind the 130 
kDa protein marker under non-reducing condition, indicating the whole molecule of 
IgG isotype (MW ~150 kDa), while two band of about 55 kDa and 25 kDa were 
observed under denaturing condition indicating the heavy chain (MW ~50 kDa) and 
light chain (MW ~25 kDa) of the IgG isotype. Western blot analysis of the purified 
bacterial-anti-YKL-40 antibody and mammalian-anti-YKL-40 antibody reacted 
strongly with YKL-40 down to 0.175 mg/L and 0.250 mg/L, respectively, whereas 
pre-immune serum showed no reaction. Cross reactivity of both of purified anti-YKL-
40 antibody showed no signal with YKL-39, AMCase and bacteria chitinase. This 
indicated that YKL-40 protein was highly specific and strongly reactive polyclonal 
antibodies against the protein of interest and hence suitable for use in electrochemical 
YKL-40 immunodetection. 
  The YKL-40 antibody was immobilized on gold disk working electrodes by 
covalent coupling with thiourea and glutaraldehyde. The electrochemical 
characteristics of modified electrodes were investigated after each assembly step. The 
quality of the thiol-based electrode surface insulation was examined with an exposure 
to a solution of 5 mM K3[Fe(CN)6] in 100 mM KCl and an acquisition of the cyclic 
voltammograms for the reversible [Fe(CN)6]
-3
/[Fe(CN)6]
-4
 redox conversion. The 
cleaned gold working electrode routinely showed the expected oxidation and 
reduction peaks of the redox couple. The redox peaks decreased more and more when 
first thiourea was self-assembled on the clean gold surface, the glutaraldehyde was 
fixed to the thiol layer, and finally anti-YKL-40 was covalently linked and added to 
the surface layout. This trend was a sign that the insulating properties of the electrode 
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increased with cumulative levels of surface modification. However, the remaining 
small electrochemical activity of the immunosensor surface after antibody 
immobilization could still be a problem with capacitance-based measurements of 
antigen binding. The modified electrode surface was thus treated with 1-
dodecanethiol to block residual bare gold surface and tune the immunosensor for the 
pure capacitive current recordings in YKL-40 quantification trials. 
  To gain highest performance of the newly-established bacterial-YKL-40 
capacitive immunosensing setting, several parameters were optimized. 
  Regeneration step to stabilized and regain the current signals for multiple uses 
of the prepared electrode seem to be critical. It was found that low pH (HCl) gave the 
highest percentage of residual activity. This probably causes the antigen bind to the 
antibody through week interactions, such as hydrogen bonds (Subramanian, 
Irudayaraj, and Ryan, 2006) as well as electrostatic interactions, hydrophobic 
interaction and Van der Waals interactions (Byfield and Abukesha, 1994). Such bonds 
can be removed lowering/raising pH in cause of protonation and deprotonation 
(Limbut, Hedström, Thavarungkul et al., 2007). HCl solution was also used as the 
regeneration solution by other immunosensing set up such as Loyprasert et al., 
(2008). In their report, HCl solution pH 2.5 (3.16 mM) show to provide the recovery, 
with the residual activity reaching almost 100% after 43 cycles of regeneration. The 
percentage of residual activity was decreased with the increase concentration of HCl 
solution, which may cause by the denaturation of the antibody due to low pH solution 
(Blackburn, Shah, Kenten et al., 1991).  
  When types of running buffer were tested, 10 mM sodium phosphate buffer, 
pH 7.0 gave the highest capacitance response and sensitivity because the ionic 
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strength of sodium phosphate buffer was higher than that of Tris-HCl and HEPES, 
which was directly related to the ionic strength (Skoog, West, and Hollar, 1996; 
Bezerra et al., 2003) and the binding affinity between the two binding partners that is 
known to be pH-dependent (Boehm, Corper, Wan et al., 2000). The association and 
dissociation affinity binding the Ag-Ab interactions are favored by low ionic strength 
and neutral pH of buffer whereas high ionic strength and extreme pH of buffer cause 
the antigen-antibody dissociation (Ramos-Vara, 2005). 
  In flow injection capacitive immunosensor system, the flow rate is one of the 
factors affecting the yield of the interactions occurring on the electrode surface. At 
low flow rate the antigen had longer time to bind with the antibody. Hence, the 
change of capacitance increased when the flow rate decreased. In our results, the 
maximum capacitive responses were observed between 50 and 100 µL/min. However 
100 µL/min was chosen to reduce the data acquiring time to 35 min compared to 60 
min when the lower flow rate was applied. 
  The last parameter to be tested was sample volume. Large sample volume that 
was injected into the capacitive immunosensor system led to an increase the amount 
of YKL-40 molecules, thereby increasing the probability of interactions on the anti-
YKL-40 immobilized electrode. A sample volume of 200 μL was test to be the best.  
  In summary the optimum condition of bacterial-YKL-40 immunosensor are 
carrier buffer 10 mM sodium phosphate buffer, pH 7.0, regeneration solution HCl 
solution at pH 2.5, flow rate 100 µL/min and sample volume 200 μL. Whereas 
mammalian-YKL-40 immunosensor are carrier buffer 25 mM sodium phosphate 
buffer, pH 7.0, regeneration solution HCl solution, pH 2.5, flow rate 100 µL/min and 
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sample volume 250 μL. These optimum operational conditions were used to evaluate 
the performance of the system. 
  Sequential injections of YKL-40 standard solution (concentrations varied from 
0.01 μg/L to 10 mg/L) were injected into the capacitive immunosensor system under 
the optimal operational condition. The both of YKL-40 immunosensors, gave a linear 
dynamic range between 0.1 µg/L and 1 mg/L, following the equation y = (12.3±0.3) 
log x + (107.4±1.4), with the limit of detection was 0.07±0.01 µg/L in bacterial-YKL-
40 immunosensor and y = (19.9±0.5) log (x) + (156.3±0.6), with the limit of detection 
was 0.08±0.02 µg/L in mammalian-YKL-40 immunosensor. At higher concentrations 
the signal became constant, indicating that all immobilized anti-YKL-40 molecules 
were occupied with the YKL-40 antigen. 
  The reproducibility and signal stability of the anti-YKL-40 modified electrode 
were investigate by continuously detecting changes in capacitance at fixed 
concentration of YKL-40 after applying HCl solution, pH 2.5 in the regeneration step. 
The electrode could be used up to 40 times and suitable for 3 days in bacterial-YKL-
40 immunosensor whereas, 50 times and suitable for 4 days for mammalian-YKL-40 
immunosensor with the percentage of residual activity of higher than 95% (%RSD < 
5). To prove that the percentage of residual activity was decreased due to the self-
assembled monolayer on anti-YKL-40 modified electrode being destroyed by the 
regeneration solution. The electrode was tested by cyclic voltammogram 
measurement. The voltammogram of anti-YKL-40 modified electrode before and 
after used were nearly the same, indicating that the self-assembled monolayer still 
remained on the gold surface but after 40 times of electrode recycling, the decrease of 
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the percentage of residual activity was seen, most likely caused by the loss of the anti-
YKL-40 antibody activity. 
  When the YKL-40 homologs (YKL-39 and AMCase) were used to test the 
selectivity of the system, only slight changes in the capacitance change were observed 
as compared with the changes obtained from YKL-40. The results showed that the 
both of anti-YKL-40 modified electrode were specific to only to the target analyte. 
  The reliability of the bacterial-YKL-40 immunosensor was accessed by 
spiking different concentrations of YKL-40 (0.5 to 50 µg/L) using the flow injection 
system. The values obtained from the capacitive immunosensor were measured the 
samples concentrations of YKL-40 were found in the same range of the injected 
concentrations (0.5 to 50 µg/L), and the percentages of recovery from the capacitive 
immunosensor and were in the range of 99.15±2.63 to 102.16±1.57. When serum 
YKL-40 samples were determined, the concentrations and the percentages of recovery 
obtained from the capacitive immunosensor were well correlated with those from the 
ELISA technique (One-Way ANOVA, p < 0.05). 
  The reliability of the mammalian-YKL-40 immunosensor system, the model 
samples was spiked at different concentrations of YKL-40 (30 to 150 µg/L); the 
concentration of YKL-40 was determined by capacitive immunosensor and ELISA 
technique. The concentrations and the percentages of recovery obtained from the 
capacitive immunosensor were well correlated with those from the ELISA technique 
(One-Way ANOVA, p < 0.05). There is no evidence for systematic difference 
between the results obtained from the capacitive immunosensor system, in-house 
ELISA and commercial ELISA. These results indicated that the developed YKL-40 
capacitive immunosensor is well suited for analysis for YKL-40 in clinical samples. 
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  However, the bacterial-YKL-40 capacitive immunosensor did not detected 
levels of YKL-40 in healthy serum (see Table 3.5); normally, the serum levels of 
YKL-40 in healthy person was about 40 µg/L (Johansen et al., 1995 and 2003, and 
Dupont et al., 2004).  Hence, mammalian-YKL-40 immunosensor was selected for all 
detections in clinical samples. 
 In the initial clinical trials with YKL-40 immunosensors serum samples from 4 
healthy persons, namely H1-H4, were screened for their YKL-40 content. The 
provided blood serum was measured in 10 times dilution to reduce the matrix effect 
from other dissolved protein. The three analysis techniques confirmed the YKL-40 
concentration in the serum of the healthy persons as 51 to 75 µg/L. A statistical data 
analysis furthermore revealed that there was no significant difference between the 
electrochemical and the conventional optical YKL-40 assaying, since the One-Way 
ANOVA, p < 0.05, fulfilling the criteria for absence of problematic significantly 
differences. In brief, the developed YKL-40 immunosensor system presents a suitable 
option for the detection of YKL-40 level in human serum. 
  Since evaluated levels of YKL-40 has been reported in several types of cancer 
such as breast cancer, colorectal cancer, ovarian cancer, small cell lung cancer, 
prostate cancer, and glioblastoma. So, we chose two type of cancer (breast cancer and 
glioblastoma) as a model for testing with YKL-40 immunosensor system with clinical 
samples. The level of YKL-40 in breast cancer patients were 40 to 400 µg/L and 
glioblastoma patients were 50 to 650 µg/L. To confirm the level of YKL-40 in breast 
cancer patients (B3) and glioblastoma patients (G1) by spiked 50 µg/L of the YKL-40 
into the obtained concentration. The values were comparable between the capacitive 
and other two ELISA techniques (One-Way ANOVA, p < 0.05) as shown in Table 
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3.6, indicating that the consistency of the estimated YKL-40 concentrations in clinical 
samples. Similar results were observed with the estimated YKL-40 from human cells 
lines, which confirmed of reliable performance our immunosensing setup. 
  However, the biological function of YKL-40 in cancer diseases is still 
unknown. It has been hypothesized that YKL-40 is a growth factor of cancer cells or 
protects them from undergoing apoptosis. High preoperative serum level of YKL-40 
in patients with primary breast cancer was an independent prognostic variable of short 
recurrence-free interval and short overall survival when axillary lymph node and 
estrogen receptor status, age, tumor size and histology, menopausal status, and serum 
YKL-40 were included in the multivariate Cox analysis (Johansen et al., 2003). 
However, elevated levels of serum YKL-40 in patients with breast cancer at the time 
of first recurrence predicted shorter time to progression and shorter overall survival 
(Jensen et al., 2003). High preoperative serum level of YKL-40 in patients with 
colorectal cancer was also a prognostic variable of short recurrence-free interval and 
short overall survival (Cintin et al., 1999). In patients with stage III ovarian cancer, a 
high preoperative plasma concentration of YKL-40 was an independent prognostic 
variable of short survival (Høgdall et al., 2003) and patients with early stage ovarian 
cancer and high serum YKL-40 had a poor prognosis (Dupont et al., 2004). Similar 
results were found in patients with a recurrence of ovarian cancer (Denh et al., 2003). 
An elevated serum YKL-40 level was also an independent prognostic variable of short 
survival in patients with metastatic prostate cancer (Brasso et al., 2006), in patients 
with metastatic renal cell carcinoma (Geertsen, Johansen, van der Maase et al., 2003), 
and in patients with metastatic malignant melanoma (Schmidt, Johansen, Gehl et al., 
2006). In patients with small cell lung cancer, a high serum YKL-40 at the time of 
 
 
 
 
 
 
 
 
132 
 
 
diagnosis and before chemotherapy was a variable for death within the following 6 
months (Jensen et al., 2004). There are no studies of serum YKL-40 levels in patients 
with glioblastoma and prognosis, but high YKL-40 gene protein (Pelloski, Mahajan, 
Maor et al., 2005) expressions in glioblastoma tumor samples were related to short 
survival. Furthermore, high YKL-40 protein expression in glioblastoma tumor 
samples was associated with poorer radiation response and shorter time to progression 
(Pelloski et al., 2005). In all eight types of solid cancer tested until now, a high serum 
YKL-40 level was related to poor prognosis. These results suggest that serum YKL-
40 may be a useful “prognostic biomarker”.  
 One study of curatively operated colorectal cancer patients has evaluated serum 
YKL-40 levels during the follow-up after surgery (Cintin et al., 2002). It was found 
that patients with elevated serum YKL-40 6 months after the operation had 
significantly shorter recurrence-free intervals and overall survival than patients with 
normal serum YKL-40 at 6 months postoperative. This result was independent of 
serum carcinoembryonic antigen levels at 6 months postoperative. Multivariate Cox 
analysis scoring serum YKL-40 as a time-dependent covariant and including age, 
Dukes' stage, gender, and tumor localization showed that a high serum YKL-40 
postoperatively in curatively operated colorectal cancer patients increased the risk of 
recurrence within the following 6 months by 6.9-fold, and the risk of death within the 
following 6 months by 8.5-fold (Cintin et al., 2002). The results of this study indicate 
that serum concentrations of YKL-40 may be useful for the monitoring of cancer 
patients. 
 In summary, the elevated plasma YKL-40 levels, compared to age-matched 
healthy subjects, are found in cancer patients with 13 different types of cancer have 
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shown that high pretreatment plasma levels of YKL-40 is related to poor prognosis. 
Highest plasma YKL-40 levels are found in patients with metastatic cancer and 
plasma levels of YKL-40 provides independent information of recurrence and 
progression free survival and of overall survival. The potential values of plasma 
YKL-40 as a biomarker in monitoring and screening of cancer need more studies, and 
its value in combinations with other biomarkers has to be determined. It is likely that 
plasma YKL-40 should be combined in panels of biomarkers for optimal clinical use, 
since most biomarkers will probably individually lack optimal sensitivity and 
specificity. A study of patients with pancreatic cancer suggests that this may be 
useful. However, YKL-40 is not cancer specific, and high plasma YKL-40 levels are 
also found in patients with diseases characterized by inflammation, tissue remodelling 
and fibrosis. Co-morbidity should therefore always be considered in cancer patients. 
  
4.2   Capacitive immunosensor for detection of YKL-39 
  To obtain the best possible analytical performance, the experimental 
parameters affecting YKL-39 capacitive immunosensor system were optimized. 
Optimum conditions were: carrier buffer 25 mM sodium phosphate buffer, pH 7.0, 
regeneration solution HCl solution, pH 2.5, flow rate 100 µL/min and sample volume 
200 μL. These operational conditions were used in all trials evaluating the 
performance of the system. 
  To identify the practical linear range, YKL-39 standard solutions of 1 ng/L to 
100 mg/L were quantified by the immunosensor system. In the calibration curves 
(plots of the capacitance change normalized to the geometric sensor area and the 
logarithm of YKL-39 concentration) the linear regression line drawn by standard 
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software followed the equation y = (16.1±0.4) log x + (137.2±2.4) with a correlation 
coefficient of 0.99. Linearity between the capacitance change and the logarithm of 
YKL-39 concentration was valid from 0.1 µg/L to 1 mg/L. The computed limit of 
detection of capacitive YKL-39 immunosensor was about 0.07±0.02 µg/L.  
  Reproducibility was investigated at optimum conditions by continuously 
detecting the change of capacitance at the same concentration of standard YKL-39 (10 
µg/L) with subsequent regeneration (HCl solution, pH 2.5) after each measurement to 
remove YKL-39 from the immobilized anti-YKL-39 on the electrode. The 
capacitance change after regeneration was used to calculate the percentage of restored 
activity of an anti-YKL-39 immobilized electrode. It became clear that a modified 
YKL-39 sensor can be regenerated and reused with good reproducibility for up to 49 
times. The electrode was tested by cyclic voltammetry before first and after last 
sample injection. The two voltammograms were similar. This means that the decrease 
in the restored activity after the 49
th
 injection was not due to the loss and/or 
destruction of the self-assembled monolayer but probably caused by the loss of anti-
YKL-39 activity. 
  Two protein homologues of YKL-39 (YKL-40 and AMCase) were used to test 
the selectivity of the capacitive immunosensor system at concentration of 1 ng/L to 
100 mg/L. As expected for an YKL-39 immunosensor, the capacitive response to 
YKL-39 increased with the analyte concentration. In contrast, the responses of YKL-
40 and AMCase were the same for all tested concentrations and in line with the 
residual response triggered by injections of blank solution (running buffer). Therefore 
it can be concluded that there a presence of the most critical interferences would not 
interfere with the detection of YKL-39 and the YKL-39 capacitive immunosensor 
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system indeed gained high specificity to YKL-39 protein from the choice of 
antibody/antigen conjugation for signal generation. 
  The routine option for the detection of YKL-39 is ELISA technique. From the 
calibration curves (the 450 absorbance vs. concentration) the linearity of optical YKL-
39 ELISA assaying was revealed as 2.5 to 125 µg/L and the detection limit of the 
method was 2.5
 
µg/L. The comparison of the linearity range and the detection limit of 
YKL-39 capacitive immunosensing and YKL-39 ELISA screening, suggested a wider 
linear range and lower limit of detection for the electrochemical approach. 
  Standard concentrations of YKL-39 in range of 0.5 to 250 µg/L were injected 
in form of model samples into the immunosensor system, of course under the 
optimum condition. Model samples were detected accurately and with good 
percentage of recovery for the concentration 0.5, 5, 25, 50 and 250 µg/L, whereas the 
indirect ELISA technique could handle only concentrations of 5, 25, and 50 µg/L with 
good percentage of recovery. Apparently, the established capacitive YKL-39 
immunosensing offered an enhanced quality of quantification over a wider range of 
analyte levels, which is an asset if working with clinical samples of unknown YKL-39 
content.     
  YKL-39 is currently recognized as a promising biochemical marker for the 
activation of chondrocytes and the progress of the osteoarthritis in human (Knorr et 
al., 2003). YKL-39 protein was, for instance, found at elevated level in synovial fluid 
from osteoarthritis patient and Jurkat and U937 cell lysates (Ranok et al., 2013). It 
was thus made a task to check the synovial fluid from a number of confirmed 
osteoarthritis patients, as well as lysates from Jurkat and U937 cells with the new 
YKL-39 selective capacitive immunosensors for the biomarkers levels and compare 
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the acquired data with the outcome of comparative assessments with an ELISA 
screen. In a pre-screen by an immunoblot assay, YKL-39 was detected in the synovial 
fluid all four samples from the osteoarthritis patients, in the Jurkat and also U937 cell 
lysates; the lysate from 293T cells, however, did not produce the specific band of the 
target protein.  
  Since synovial fluid and cell lysates are complex mixtures of a variety of 
biochemical species the liquids were not straight used for capacitive and ELISA 
analysis but subjected to a10 fold dilution with 25 mM sodium phosphate buffer, pH 
7.0 first in order to minimize contributions of non-targeted matrix components to 
signal generation. Both the electrochemical capacitive and the optical ELISA methods 
quantified YKL-39 in the synovial fluid of osteoarthritis patients between 59 and 106 
µg/L. Their application to an analysis of Jurkat and U937 cell lysates revealed 26 and 
10 µg/L, respectively, whereas, the 293T cell lysate was reported to be YKL-39 free. 
Finally, the two methods reported the absence of YKL-39 in 293T cell lysates. 
Altogether, these results were in good agreement with own immunoblot control 
measurement and also confirmed what was known from the literature survey of the 
subject. 293T cell lysates spiked with 20 and 30 µg/L of YKL-39 presented another 
type of model sample that the proposed immunosensor scheme was applied to adjust 
YKL-39 concentrations of 20 and 30 µg/L were quantified with the capacitive 
immunosensors and control ELISA with a percentage of recovery that was close to 
100%. The values were comparable between the capacitive and ELISA techniques 
(One-Way ANOVA, p < 0.05) as shown in Table 3.9 and 3.10. This commonly good 
recovery was another proof that capacitive YKL-39 immunosensors were well-
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working analytical tools for quantitative and qualitative identification of the presence 
of a renowned osteoarthritis biomarker in real biological sample environment. 
The observed equivalency in performance for all measurements on the 
samples of this study is good evidence that capacitive electrochemical immunosensing 
in general functions well and has the potential to be used as a competitive alternative 
option for laboratories aiming on an effective analysis of disease markers related to 
human chitinase-like proteins.   
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CHAPTER IV 
CONCLUSION 
 
The recombinant YKL-40 polypeptide lacking its 20-amino acid signal 
sequence was successfully expressed in an insoluble form with E. coli strain M15 
(pREP) as host. The protein was expressed as a His8/YKL-40 fusion protein with the 
total molecular weight of approximately 40 kDa. The insoluble YKL-40 protein was 
solubilized in 8 M urea and further purified by Ni-NTA agarose affinity column 
chromatography. Purified YKL-40 protein was used for the production of YKL-40 
polyclonal antibody. The anti-YKL-40 strongly reacted with YKL-40 target protein 
and evaluation of cross-reactivity against other members of GH-18 (YKL-39, 
AMCase, and bacteria chitinases) revealed no interaction of the polyclonal antibody. 
Purified anti-YKL-40 antibody was immobilized on disk-shaped smoothly 
polished gold working electrodes by covalent coupling the protein to a thin thiourea 
film via glutaraldehyde as chemical crosslinking reagent. The resulting YKL-40 
immunosensors were employed as novel analytical tools in an electrochemical flow 
cell and used to quantify YKL-40 antigen levels of injected samples by an analysis of 
their capacitive current response to ms-long simulative potential pulses.  Optimum 
conditions for capacitive YKL-40 immunosensing were the use of 10 mM sodium 
phosphate buffer, pH 7.0, as running buffer in the tubes of the flow system, use of 
HCl solution, pH 2.5, as regeneration solution that broke antibody/antigen conjugates
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apart after a sample injection and antigen capture, and the choice of a flow rate and 
sample volume of 100 µL/min and 200 μL, respectively. The basic performance of the 
system and its power for the accurate quantitative detection of YKL-40 were 
evaluated under optimal conditions. The linear dynamic range of the capacitive YKL-
40 screen spread from 0.1 μg/L to 1 mg/L, while its limit of detection was found to be 
0.07±0.01 µg/L. Specificity tests revealed that anti-YKL-40 modified gold disk 
electrodes reacted with changes in capacitance only against an exposure to YKL-40, 
while even structurally similar protein relatives could not trigger a measurable sensor 
response. Stability tests, on the other hand, disclosed a functional applicability up to 
40 times of YKL-40 sample injections or about three days continuous operation in the 
flow-based electrochemical workstation. Capacitive YKL-40 immunosensor 
identified in the flow detection mode their protein target in spiked model samples 
with excellent recovery rates and in very good agreement with comparative data from 
parallel assessment via ELISA testing. The content of spiked serum samples was 
recovered accurately and was consistent with the outcome of ELISA-based tests. 
Finally, the effective application of the developed capacitive YKL-40 immunosensing 
for the analysis of blood serum samples from some breast cancer and glioblastoma 
patients and lysates from model cells with and without the possibility of cellular YKL 
secretion was successful and confirmed through close matches with complementary 
ELISA data the strong potential of the methodology as a useful tool for analytical 
YKL-40 cancer biomarker screening.     
    YKL-39 antigen and antibody was available from previous research work in 
the group and the affinity couple was, the relevance of YKL-39 as potential 
osteoarthritis biomarker in mind, explored for capacitive YKL-39 immunosensor 
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construction and application of completed versions for YKL-39 screens in model 
(spiked buffer) and real (synovial fluid of osteoarthritis patients) samples. When used 
with pre-identified optimal assay conditions, the linearity of the sensor response, the 
sensor stability and the recovery rates for model sample determinations was as good 
for YKL-39 immunosensors as for the YKL-40 variant described above (here: linear 
range from 0.1 µg/L to 1 mg/L; operational stability up to 49 sample injections and 
percentage of recovery close to ideal 100%). Apparently, the method can measure the 
YKL-39 content of synovial fluid of osteoarthritis patients and cell lysates of Jurkat, 
U937 and 293T in good agreement with complementary ELISA. Thus, capacitive 
YKL-39 immunosensing holds great promises as complementary optional tool for an 
early detection of joint osteoarthritis, which currently cannot be achieved at the onset 
or early development stages because of a lack of a powerful enough analytical 
techniques for this biomarker. 
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